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ABSTRACT
RNA maturation involves several steps prior to export of the mRNA out of the
nucleus and translation in the cytoplasm. PremRNA 3’end processing is one of such
steps, and comprises the endonucleolytic cleavage and polyadenylation of the 3’end of
the premRNA. These two steps involve more than 14 processing factors that coordinate
multiple proteinprotein and proteinRNA interactions necessary to coordinate efficient
cleavage and polyadenylation. To date, many of these interactions have been
investigated biochemically and require additional structural characterization both to
confirm and highlight key residues involved in substrate contacts. Further structural
characterization will also open investigation into the mechanism of 3’end processing by
providing structural insight into the coordination of multiple binding components. The
cleavage factor Im, CF Im, is a component of the 3’end processing machinery and plays
an important role early, during endonucleolytic cleavage, and additionally to increase
polyadenylation efficiency and regulate poly(A) site recognition. CF Im is composed of a
small 25 kDa subunit, CF Im25, and a large, either 58 kDa, 68 kDa, or 72 kDa subunit.
The 25 kDa subunit of CF Im interacts with both the RNA and other processing factors
such as the poly(A) polymerase, Clp1, and the larger subunit of CF Im. It is our goal to
crystallize CF Im25 alone and in complex with one of its interacting partners to better
understand CF Im25 contributions to premRNA 3’end processing.
The structural investigation of CF Im25 and its binding partners has accomplished
four major objectives: 1) Characterized the crystal structure of CF Im25 alone and bound
to diadenosine tetraphosphate, 2) Provided insight into the oligomeric state of the CF Im
complex, 3) Determined the binding properties of the Nudix domain of CF Im25 and its
function in 3’end processing, 4) Further characterize the interactions between CF Im25
and PAP, CF Im68, and Clp1. These results demonstrate CF Im25 is a dimer both in
solution and in the crystal suggesting that it is likely to be a dimer in the CF Im complex.
The nucleotide binging capability of CF Im25 has no apparent role in 3’end processing in
vitro but may provide a function outside of 3’end processing or may directly be involved
in RNA recognition. The additional investigation of complex interactions with the
25 kDa subunit of CF Im25 suggests that although these factors interact during the 3’end
processing event additional mechanisms may play a role in stabilizing those interactions.
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CHAPTER 1:
Eukaryotic premRNA 3’end Processing

1

Eukaryotic premessenger RNA undergoes several steps of processing prior to
export from the nucleus and translation in the cytoplasm.

These steps include the

addition of a 5’ 7methylguanosine (m7G) cap, splicing of intronic messages, and lastly,
cleavage followed by polyadenylation as shown in Figure 1. These processing steps are
thought to be tightly coupled and occur cotranscriptionally by recruitment of processing
factors to the actively transcribed RNA via interaction with the carboxy terminal domain
(CTD) of RNA polymerase II (1). This has also been demonstrated in vitro, where it is
possible to monitor transcription and the subsequent processing steps individually. In
doing so it becomes evident that not only is processing tightly coupled to transcription
but each processing event is capable of enhancing the subsequent event (2, 3). During
transcription this occurs through interaction with the CTD. The CTD is composed of
tandem heptad repeats with the consensus sequence, Y1S2P3T4S5P6S7. Phosphorylation
and dephosphorylation of specific residues within the CTD consensus sequence, in
response to transcriptional checkpoints, is crucial for cotranscriptional processing by
recruitment of premRNA 3’end processing factors to the site of active transcription (4,
5). This coupling event promotes rapid mRNA stabilization by protection of the initially
transcribed premRNA and additionally provides a platform to tether processing factors
to each other.
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Capping of the premRNA
The initial step in premRNA 3’end processing is capping. The capping process
is orchestrated by phosphorylation of serine residues within the CTD heptad resulting in
recruitment of the mammalian capping enzyme, CE. CE contains both the RNA
triphosphatase and guanylyltransferase activities and was identified by crosslinking
experiments to associate with the elongation complex at the promoter region. In yeast, the
triphosphatase and guanylytransferase activities are contained on two separate genes (6).
The 7methyltransferase has a more distributive binding pattern and is associated with the
elongation complex within the coding region as well as at the 5’ end of the gene, as
demonstrated by crosslinking experiments (4). This finding suggests that CE is at the
transcriptional start site at the time of transcriptional initiation to cap the 5’ end once
available. The capping reaction begins with the removal of a phosphate from the 5’ end
of the transcript by the RNA 5’ triphosphatase activity of the CE.

The

guanylyltransferase activity then adds a guanosine residue in an inverted position via a
5’5’ triphosphate linkage and the N7 position of guanosine is subsequently methylated
by 7methyltransferase. Upon methylation the m7G cap structure is bound by the cap
binding complex (CBC) at the 5’ end of the mRNA. The CBC bound cap plays an
important role, preventing degradation of the RNA by 5’3’ exonucleases and is
additionally important in enhancing translation in the cytoplasm along with other
translation initiation factors (6, 7). Finally, in vitro, the cap structure has been shown to
stimulate the next processing step, splicing, by enhancing the splicing reaction of capped
vs. uncapped RNAs (6).
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The Splicing Reaction
Following the addition of the cap structure, premRNA 3’end processing
continues with the removal of intronic RNA during the splicing process. The splicing
machinery, also termed spliceosome, consists of five RNA protein complexes termed U
snRNPs, small nuclear ribonuclear protein particles, along with multiple serinerich (SR)
proteins. The snRNPs consist of U1, U2, U4, U5, and U6 and include several transient
splicing factors. There is some evidence to suggest that the splicing event is influenced,
as is the case for the capping reaction, by phosphoCTD interactions (1, 8). Yeast
Prp40p, a component of U1 snRNP, was shown to interact directly with the
phosphorylated CTD (9). A similar role of phosphoCTD interactions in splicing has yet
to be demonstrated in the mammalian spliceosome.
Splicing occurs in two steps and is controlled by recognition of sequence elements
within the RNA. Splicing begins with 5’ splice site cleavage, yielding a lariat structure.
Second, cleavage occurs at the 3’ splice site followed by exon ligation. Spliceosome
assembly is initiated with the binding of U1 snRNP to the 5’splice site by recognition of
the mammalian consensus sequence AG/GURAGU. SF1/mBBP recognizes the
branchpoint sequence, YNYURAC, at the 3’ end along with U2 auxiliary factor’s, U2AF,
binding at the pyrimidine tract and 3’ AG splice site. U2 snRNP binds, although weakly.
These initial binding steps form the early (E) complex. The next step in splicing
is the formation of the A complex, which occurs when U2snRNP binds at the
branchpoint.

The association of additional factors U4/U6U5 snRNP forms the B
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complex. Subsequent to B complex formation, a rearrangement of the spliceosome
occurs to form the active catalytic C complex (10).
Along with snRNPs, serine/argininerich proteins (SR proteins) function in the
splicing mechanism. SR splicing factors are involved in the initial recruitment of U1
snRNP and U2AF as well as in the later A and B complex transition and C complex (10).
They have been shown to have a role in the regulation of 3’ splice site selection by
binding at an exon sequence and enhancing the splicing of the adjacent intron (10).
Additionally, they can promote the recognition of alternative 5’ splice sites and function
in constitutive splice site selection by defining small exon borders amongst larger introns
(11). Splicing has also been shown to couple events in RNA processing and is evident by
the stimulation of the splicing event by poly(A) polymerase’s (PAP) recruitment of a
component of U2AF, U2AF 65, to the 3’ splice site. The coupling of splicing and
processing events is also made evident with the stimulation of polyadenylation via U2AF
65’s interaction with the 59 kDa subunit of CF Im (12).

premRNA 3’end Cleavage and Polyadenylation Events
The newly capped and spliced premRNA in eukaryotes is processed in a twostep
reaction consisting of endonucleolytic cleavage of the premRNA followed by addition of
a poly(A) tail at the 3’ end of the upstream cleavage product (1315). Many of the factors
present in the mammalian premRNA 3’end processing machinery are conserved in the
yeast system. Although I will be focusing primarily on the mammalian system, I will
provide a brief summary of premRNA 3’end processing events in yeast.
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Yeast premRNA 3’end Processing
Much like the mammalian system, yeast premRNA 3’end processing involves
recognition of sequences elements for regulation and efficient processing.

These

elements are slightly different in sequence context from the mammalian system and
because of such differences these elements can be recognized by different factors.
The yeast sequence elements that dictate proper and efficient cleavage and
polyadenylation are the AUrich element or efficiency element (EE), the Arich
positioning element (PE), the cleavage site, and the Urich elements that border the
cleavage site. The efficiency element UAUAUA, with U at both the first and fifth
positions is the most efficient for processing, although it is not critical for the cleavage
reaction (16, 17). The PE is similar to the mammalian AAUAAA hexamer or
polyadenylation signal (PAS) in dictating the proper 3’end processing position. The
optimal PE sequence context in yeast is AAUAAA or AAAAAA and is positioned 1030
nucleotides upstream of the cleavage site. The cleavage site or poly(A) site consists of the
sequence Py(A)n and functions along with the upstream sequence element (USE) and
downstream sequence element (DSE) to specify proper cleavage site selection (18).
The yeast premRNA 3’end processing machinery consists of more than 20
processing factors. These factors can be broken down into smaller subcomplexes of
which core homologs can be found in the mammalian system (Table 1). In vitro, the
yeast cleavage reaction requires cleavage factor IA (CF IA), cleavage factor IB (CF IB),
and cleavage factor II (CF II). Multiple other protein factors copurify with the cleavage
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and polyadenylation machinery and are important for increasing the efficiency and
linking transcription to 3’ premRNA processing (13, 19).
The crystal structure of components of CF IA, Clp1ATP in complex with the
Clp1 binding region of Pcf11 reveals structural interactions, which are likely to be
present in the mammalian homologues (Figure 2). A high structural similarity with the
mammalian homologues is expected due to high sequence conservation within the
Clp1/Pcf11 binding interface. The Clp1 component has a Walker A motif which harbors
the ATP nucleotide binding site where the base selectivity is mediated by interaction of a
glutamate residue from the amino terminal domain with the N6 position of adenine (20).
Additionally, the structure of the RNA recognition motifs (RRM) of Hrp1, a CF IB
factor, has been solved in complex with the AUrich efficiency element (21). This
structure depicts the recognition of a six tandem repeat of AU by two RRMs of Hrp1
arranged in parallel. The RRMs adopt a more closed conformation upon RNA binding
creating a noticeable RNA binding cleft between the two RRMs. This is most apparent in
solution, where the RRMs behavior alone resembles two independent rigid bodies that
become tightly associated in RNA titration experiments in solution (21).
PremRNA 3’end processing concludes with the addition of the poly (A) tail by
Pap1. Interestingly, the poly(A) tail length in yeast is significantly shorter than in the
mammalian counterpart, averaging only 5070 nucleotides (17). There are several crystal
structures of Pap1 including a more recent crystal structure of Pap1 in complex with 25
residues of Fip1, a component of the complex PF 1. The Fip1 sequence is highly
divergent across species, including the Pap1 binding region which was crystallized (22).
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Fip1 is predicted to be highly flexible as suggested by POODLE plots of the protein’s
disordered regions and suggested by the small fragment crystallized (23). Other crystal
structures of Pap1 were captured in the closed, cordycepin (3’dATP), and ATP and
oligo(A) bound states (2426).

Pap1 exhibits a three domain polymerase structure

composing a Nterminal, central, and a C terminal domain distinct in Pap1 and involved
in RNA primer binding. The initial structures of Pap1 attempted to address the domain
movements of the protein necessary to facilitate ATP recognition and catalysis. In doing,
so Balbo et al. 2007 described a closed conformation of Pap1 not previously described
where flexibility depends on two hinge regions located in the middle domain.
Additionally, superposition of ATP or ATP analog into this structure suggests possible
base specificity through contacts with a neighboring asparagine residue (24). The most
recent structure of a Pap1 ternary complex with ATP and oligo(A) was obtained by a
mutation of one of the catalytic aspartates, D154A, capturing the enzyme in a closed
conformation with RNA bound (Figure 3) (25). Overall, the ternary complex provides
details of the path of the RNA and possible proteinRNA interactions although Bfactors
of the adenine residues close to the active site are elevated.
Due to similarities between the yeast and mammalian systems the structural data
of yeast premRNA 3’end processing factors can provide further insight into the
mechanism of mammalian 3’end processing which will be introduced below.
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Mammalian Cleavage and Polyadenylation
Mammalian endonucleolytic cleavage of the premRNA and addition of a
poly(A) tail at the 3’ end are additionally coupled as seen with capping and splicing.
This coupling requires multiple proteinprotein and proteinRNA interactions and has
been shown to require ATP for the polymerization reaction, cleavage, and the recruitment
of cleavage factors to the premRNA in a substrate specific manner. In addition to the
ATP requirement, creatine phosphate (CP) has also been proposed as a necessary factor
for efficient premRNA 3’end processing.

CP’s role was initially thought to be

necessary for replenishing the ATP pool in the nuclear extract due to contaminating
ATPases. However, the lack of CP hydrolysis to compensate for a diminishing ATP pool
suggests otherwise (14). CP may in fact play a role as an effector molecule for a
component of the cleavage and polyadenylation machinery.
Despite its seemingly simplistic twostep mechanism, it has been estimated that
more than 14 factors are required for mammalian premRNA 3’end processing and both
cleavage and polyadenylation steps are crucial for transcript fidelity and translation. This
is evident when disruption of polyadenylation occurs and results in the loss of
cytoplasmic transport and a subsequent decrease in protein expression (16). Furthermore,
addition of a poly(A) tail and binding of the poly(A) binding protein (PABP) promotes
stability at the 3’end, the primary target of degradation in the cytoplasm. The processing
of the 3’end also enhances the translation of the mRNAs by the presence of both the cap
and poly(A) tail. Lastly, premRNA 3’end processing is crucial in the coupling of
transcription with further processing events in which 3’ processing factors interact with
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the CTD of RNAP to control transcriptional initiation and to signal termination via
poly(A) site strength and tail synthesis (6).
The factors that are necessary and sufficient to reconstitute cleavage and
polyadenylation in a mammalian in vitro system are poly(A) polymerase (PAP), cleavage
and polyadenylation specificity factor (CPSF), cleavage stimulation factor (CstF),
cleavage factor Im (CF Im), cleavage factor IIm (CF IIm) and the nuclear poly(A) binding
protein 1 (PABPN1) (Figures 4 and 5). Recruitment of the mammalian cleavage and
polyadenylation machinery to the newly formed 3’end of the premRNA relies on the
recognition of two conserved sequence elements: the highly conserved hexamer
AAUAAA polyadenylation signal (PAS) recognized by CPSF and a GU/Urich sequence
downstream of the cleavage site recognized by CstF. Additionally a set of UGUA
elements, a third sequence element found upstream of the cleavage site and not as
universally conserved, is recognized by CF Im and functions in poly (A) site selection (27,
28). The AAUAAA sequence is found in 70% of sequenced human and mouse mRNAs
of which the second most common sequence is AUUAAA (16). The importance of the
high conservation in the sequence context of the hexamer is highlighted in  and 
thalassemic patients where a point mutation occurs in the last position of the conserved
hexamer resulting in diminished levels of mRNA (29). Of additional importance, is the
positioning of the hexamer 1030 nucleotides downstream of the poly(A) site. Deletions
within this region have been shown to result in the formation of a new cleavage site,
which reconstitutes the original length of the deleted portion. The GU/U rich DSE is
positioned approximately 30 nucleotides from the cleavage site and has a lower sequence
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conservation than the PAS hexamer. The remaining cleavage site element is found
between the PAS hexamer and the DSE with an optimal cleavage site containing CA (13,
16).
The cleavage event is initiated upon recognition of the conserved hexamer, by the
160 kDa subunit of CPSF, and binding at the GU/Urich DSE by CstF64 (Figure 2). The
recognition of these elements is enhanced by loading both CPSF and CstF onto the pre
mRNA during transcription at the promoter region. The stabilization of both CPSF and
CstF on the RNA occurs through interactions at the 5’ end of the RNA with the CBC.
This interaction effectively links the 5’end and the 3’end of the premRNA during the
capping event and demonstrates crosstalk amongst processing factors. In vitro capping
experiments with CBC depleted nuclear extracts have demonstrated CBC stabilization of
3’end processing factors primarily affects cleavage, having no effect on polyadenylation.
In addition, in vitro reconstitution of the cleavage activity with recombinant proteins does
not fully restore the cleavage activity with the addition of the CBC. This suggests the
link between the 5’end and 3’end is facilitated by additional processing factors through
interaction with the CBC (30).
The additional coupling of the cleavage reaction to transcription is demonstrated
by the increase in the efficiency of the cleavage reaction in the presence of the CTD (31).
CPSF consists of five factors CPSF30kDa, 160kDa, 73kDa, 100kDa, and Factor
Interacting with Pap1 (Fip1), all of which are required for cleavage and/or
polyadenylation. It has been suggested that the 160 kDa subunit alone recognizes and
binds at the hexamer, although this interaction is likely to be stabilized and strengthened
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by its other components. Stabilization at the conserved hexamer by CPSF160 requires
CstF binding and most likely CF Im. The 30 kDa subunit of CPSF can be crosslinked to
the hexamer RNA sequence and may also contribute to RNA binding via contacts with its
five zinc finger domains and zinc knuckle. It has been previously suggested that the 30
kDa factor may not be a necessary component of CPSF due to CPSF30’s weak
association with its other components (14). The evidence stemmed from two published
reports detailing the purified CPSF complex in which CPSF30 did not appear on an SDS
PAGE gel (32, 33). More than likely the association of the 30 kDa subunit with its other
components is enhanced during the appropriate processing events and has a more
transient interaction otherwise.
Like many of the processing factors, CstF is a multicomponent complex
consisting of a 50 kDa, 64 kDa, and 77 kDa subunits. The 77 kDa subunit is involved in
bridging both the 64 kDa and 50 kDa subunits.

The 77 kDa subunit from

Encephalitozoon cuniculi, a protozoan parasite, crystallizes as a homodimer containing
only  helices distinct to the HATrepeat family (34). The dimer interaction is also
consistent with the crystal structure of the murine CstF77, which represents the entire 77
kDa structure except for an estimated 200 residues at the carboxy terminus (Figure 6)
(35, 36). In addition, NMR structures for the N terminal and C terminal regions of the
64 kDa subunit have been solved (36, 37). The Nterminus of the 64 kDa subunit has the
characteristic RRM fold that most closely resembles that of U1A (36). There is no
structural data so far for the 50 kDa subunit of CstF. CstF50, aside from its role in 3’
processing, provides a cotranscriptional link between the damage repair pathway
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through its interaction with the repair proteins BRCA1/BARD1 and the CTD following
cellular damage (38, 39).
CF Im is another component of the cleavage machinery and is an oligomer
composed of a small 25 kDa subunit (CF Im25, also referred to as CPSF5 or NUDT21)
and a larger subunit of either 59 kDa, 68 kDa, or 72 kDa (40). Despite the presence of an
RNA binding domain in the 68 kDa subunit, high affinity RNA binding requires both the
25 kDa and 68 kDa subunits and is facilitated by the 25 kDa amino terminal region and
the arginine/serine rich region of the 68 kDa subunit (41). As presented so far, most of
the cleavage factors associate with each other as well as the RNA. It can be suspected
that following a weaker binding by individual factors to their recognition sequences,
there is a rearrangement of the RNA, facilitating these factors to come into close contact.
This rearrangement then allows for multiple proteinprotein interactions and strengthens
both binding to the recognition elements and complex formation. As of yet there is no
data to indicate a specific change in the RNA structure upon complex formation. These
events also are thought to occur in an orchestrated manner to increase efficiency of the
reaction.

This is suggested by the stimulation of the cleavage reaction following

preincubation of CF Im with the RNA and subsequent addition of CstF, PAP, and CPSF
(40). The stimulation of cleavage only occurs when CF Im is preincubated with RNA,
suggesting CF Im ‘s proficient binding to the RNA could then allow other cleavage
factors to bind more efficiently. Alternatively the cleavage reaction occurs in a step wise
order of component addition.
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In addition to the factors previously mentioned, the cleavage reaction requires
CF IIm and PAP to proceed. CF IIm is the least understood of the cleavage factors and
presently does not have all of its components identified and purified to homogeneity (14).
Initial characterization of CF IIm divides it into two subcomponents, characterized by two
separate functions: cleavage stimulatory activity and facilitated proteinprotein
interactions.

The first subcomplex of CF IIm interacts with CPSF and CF Im and

fractionates with the Clp1 protein. The other subcomplex of CF IIm is thought to be
involved in stimulating the cleavage event (6). The recruitment of PAP to the assembled
cleavage complex involves interactions with CPSF to increase binding at the hexamer
and is likely the predominant mechanism for coupling cleavage to polyadenylation. This
positions PAP at the poly(A) site following cleavage. The cleavage event occurs 2030
bases downstream of the conserved hexamer. The 73 kDa subunit of CPSF is a possible
candidate as the endonuclease in this event. The endonuclease activity of CPSF73, based
on in vitro data, is dependent upon the presence of calcium for efficient cleavage and is
sequence independent. The specificity of the cleavage event in vivo, by CPSF73 could be
directed by the preferential binding of CstF64 and CPSF160 to either the GU/Urich or
PAS site. Additionally, there is no described requirement in the processing reactions for
calcium and may not be necessary in vivo (42). Further investigation to characterize
CPSF73’s involvement as the endonuclease in the cleavage process should be evaluated
in vitro with CPSF73 depleted nuclear extracts as well as in the presence of the cleavage
components to restore the specificity of CPSF73 and the calcium requirement.
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In conjunction with the biochemical investigation of the endonuclease activity of
CPSF73, Mandel et al. 2006 solved the crystal structure of both the 73 kDa subunit and
the yeast 100 kDa subunit (Ydh1p) of CPSF (Figure 7). CPSF73 and CPSF100 both
belong to the metallolactamase superfamily (MBL) of zinc dependent hydrolases.
CPSF73 has the structurally conserved metallo active site, 4 of the 5 conserved MBL
motifs, and a CASP domain. Interestingly, CPSF100 which reflects a similar structural
layout, lacks the coordinating ions necessary for catalysis, suggesting a nonfunctional
MBL enzyme. The active site of CPSF73 coordinates two zinc ions and a sulfate ion.
Appropriately, with other members of the metallo superfamily, CPSF73 has a hydroxide
ion positioned near the sulfate, which mimics the potential substrate binding position.
The hydroxide ion is a potential nucleophile for the hydrolysis reaction and is a strong
indication of a potential endonuclease activity (42).

Follow up research has added

further insight into the role of the endonuclease with the investigation of histone mRNA
processing (43). Point mutations of critical MBL residues based on the structure and
sequence conservation in both CPSF100 and CPSF73 are inhibitory to the endonuclease
activity necessary for creating the histone new 3’end (43). This recent finding suggests
both the 100 kDa and 73 kDa function together in the 3’ –end endonuclease cleavage of
all premRNAs. This is due to core conservation between histone 3’end maturation and
the factors involved in establishing the new 3’end of all other premRNAs, aside from
proteins involved in the adenylate tail synthesis.
As mentioned previously, cleavage generally occurs on the 3’ side of an A, with a
preference for a CA at the site of cleavage. Once the endonuclease has cleaved the pre
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mRNA, CstF and CF IIm are released with the downstream cleavage fragment allowing
polyadenylation to proceed. The cleavage reaction is tightly coupled to the recruitment
of the remaining factors in the last processing step, polyadenylation.
The polymerization of the adenosine tail requires at minimum PAP, PABPN1,
and CPSF. CPSF160 and PABPN1 confer an increase in binding and specificity to the
otherwise, nonspecific and distributive RNA polymerase, PAP. Fip1 in conjunction with
CPSF160 functions to recruit PAP to the poly(A) site to stimulate polymerase activity by
binding Urich USEs within the premRNA. The recruitment of PAP for efficient
polyadenylation also requires interaction with CF Im in conjunction with Fip1 and
CPSF160, where CF Im association with Fip1 is involved in PAP stimulation (28, 44).
hFip1 interacts via its Cterminal arginine and arginine/glutamic acid region with the
RBD and Nterminal region of PAP (44). In contrast, yeast Fip1 alone inhibits Pap1’s
processivity and switches Pap1 to a distributive mode in vitro. However, this inhibition
can be alleviated by contributions from subunits of CPF for Pap1 stimulation (45).
The polymerization activity is regulated both in vivo and in vitro by multiple
phosphorylation states within the carboxylterminal domain of PAP.

In vivo, this

regulation coincides with the activity of the cell cycle where phosphorylation of the C
terminal region of PAP decreases enzyme activity.

The kinase most likely to be

responsible for modulation of the phosphorylation state of PAP is mitosis promoting
factor (MPF). This is suggested by the several consensus sequences contained within the
Cterminal region of PAP that are specific for MPF binding. In addition, MPF has been
shown to phosphorylate PAP both in vivo and in vitro (14). The processing complex can
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additionally be modulated by the acetylation of lysines 635/644/730/734 of PAP and
lysine 23 of CF Im25, by the Creb Binding Protein (CBP), as shown by
immunoprecipitation experiments with an acetylatedlysine antibody and subsequent
identification by mass spectrometry (46). In vivo, however, acetylation of lysines
635/644/730/734 of PAP and lysine 23 of CF Im25 has been shown to disrupt the
interaction between CF Im25 and PAP in COS7 cells treated under acetylation conditions
and cotransfected with CF Im25, CF Im68, and PAP (46). Interestingly, the carboxy
terminal region of PAP is not crucial for maintaining CF Im25 interaction in vitro, as
demonstrated by pulldown experiments with recombinant CF Im25 and a carboxy
terminal truncated PAP (Figure 8) (41). This finding suggests a transient interaction
could exist between PAP and CF Im 25, which does not require the Cterminal domain
and remains an area that needs to be further investigated. In addition, an indirect or direct
interaction between PAP and CF Im occurs during processing, via CF Im25 and other
processing components. This interaction stabilizes the processing complex whereby
acetylation may play a role in the regulation of the processing complex through the
disruption of CF Im and PAP.
In vitro, the polymerase activity of PAP increases 30 100 fold with the addition
of manganese in comparison to magnesium. Manganese functions to stimulate poly(A)
addition by increasing the binding of PAP to 3’ends of the RNA (47, 48).

The

polymerization event in vivo involves the binding of two magnesium ions to the
conserved aspartic acid residues within the active site of PAP. Metal binding allows
coordination of the incoming ATP and stabilization of the transition state following AMP
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addition. The crystal structure of bovine PAP provides insight into the active site
mechanism of polyadenylation and the polymerases ability to discriminate against other
nucleotides to only incorporate adenosine into a growing adenylate tail (48). A carboxy
terminal truncation mutant of PAP (PAP513) bound to cordycepin triphosphate was
crystallized lacking the Cterminal 226 residues (Figure 9). Importantly, this mutated
construct can still be stimulated by CPSF and PABPN1 and additionally PAP513 can
interact only in the presence of oligo(A) with PABPN1 (49, 50). PAP belongs to the
superfamily of nucleotidyl transferases and as such contributes three conserved aspartic
acid residues and a helical turn motif that have been shown to be important for
phosphoryl transfer amongst family members. The three aspartic acid residues and a
helixturn motif are involved in coordination of the bound nucleotide. Selectivity for ATP
over competing nucleotides is via N7 contacts to one of the catalytic aspartic acids and
stabilization of the adenine ring via hydrophobic interactions with two neighboring valine
residues (50). The binding of PAP to RNA is relatively weak and nonspecific and only
has maximum processivity of polymerization in conjunction with PABPN1 and CPSF.
PABPN1 is also involved in tail length control and restricts the polyadenylated tail length
to approximately 250 nucleotides in higher eukaryotes whereby, upon completion the
mRNA can be efficiently transported out of the nucleus into the cytoplasm (13, 14).

CF Im
The coupling of preceding steps, such as transcription, capping and splicing in
premRNA 3’end processing is important for the efficiency of both cleavage and
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polyadenylation. This relies on the crosstalk of multiple proteinprotein assemblages that
initially form during the cleavage step and rearrange subsequently to function in
polyadenylation. Much of what we know about complex formation of processing factors
on the premRNA and its regulation has been investigated biochemically. A structural
characterization of individual and multicomponent processing factors will elucidate the
domain interactions important for the premRNA 3’end processing mechanism that
cannot be deciphered by biochemical means. We chose the structural investigation of the
25 kDa subunit of CF Im (CF Im25) because of its role in cleavage and stimulatory role in
polyadenylation. The 25 kDa subunit of CF Im interacts with multiple players of the
cleavage and polyadenylation machinery, directly or as a complex with its larger subunit
(Figure 10). In addition, CF Im25 plays an important role in promoting complex
recognition and regulation of poly(A) site selection.
As mentioned previously, CF Im is an oligomer composed of a small 25 kDa
subunit (CF Im25, also referred to as CPSF5 or NUDT21) and a larger subunit of either
59 kDa, 68 kDa, or 72 kDa (40). Homologs of CF Im subunits are also found in cDNA
databases of Caenorabditis elegans, Drosophila melanogaster, and plants. The three
larger subunits share substantial sequence homology. They are encoded on two different
genes and the 72 kDa subunit is a splice variant of the 68 kDa polypeptide. CF Im can be
reconstituted in vitro from the 25 and 68 kDa subunits (40, 51). The 68 kDa subunit has
a domain architecture similar to splicesomal SRproteins. The 68 kDa subunit contains
an amino terminal RNP domain, central proline rich region, and a carboxyl terminal
arginine and serine rich region (RS) (Figure 11). The interaction of CF Im 68 with
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components of the human splicesome suggests a link between 3’ premRNA processing
and splicing (52). It has been demonstrated that the 25 kDa, 59 kDa, and 68 kDa,
subunits individually bind RNA in the absence of other processing factors as
demonstrated by UV crosslinking (40). More recently, and as mentioned previously,
assays involving the 68 kDa and 25 kDa subunits suggest both are necessary for efficient
RNA binding. RNA binding is facilitated primarily by the amino terminal region, amino
acids 1160 of CF Im 25, and the RS region of CF Im 68, as demonstrated with pulldown
assays using truncation mutants of both proteins (41).

Both the cleavage and

polyadenylation steps involve a CF Im complex rather than individual components of
CF Im, which suggests a cooperative RNA binding function. In addition to characterizing
the RNA binding potential of CF Im, Dettwiler et al. 2004 demonstrated the portions of
CF Im25 that are sufficient to interact with other processing factors. The entire CF Im
25 kDa subunit is necessary for the interaction with CF Im 68 kDa subunit and likely
occurs through the Nudix region (nucleoside diphosphate linked to another moietyX) of
CF Im 25 based on the charge distribution. The interaction of the 25 kDa subunit with the
68 kDa subunit relies on the RRM region of the 68 kDa subunit. Recently, CF Im, has
also been implicated in a role in the regulation of poly(A) site recognition by preferential
binding to UGUAN sequences contained within the poly(A) site region (28).

The

binding of CF Im to UGUAN containing sequence elements around the poly(A) site
suggests an additional mechanism to select for the noncanonical hexamer sequences and
alternative poly(A) sites that exist. SELEX analysis identified short UGUAN containing
RNAs with high affinity for recombinant CF Im.
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The addition of these UGUAN

containing RNAs to cleavage and polyadenylation reactions inhibited the poly (A) site
cleavage by sequestering CF Im in the nuclear extract (27). CF Im is also involved in
stabilizing CPSF at the conserved hexamer through interactions with the 160 kDa subunit
(40). In vitro, binding assays with recombinant proteins suggest only a weak interaction
between CF Im25 and CPSF160 (41). This interaction may require the 68 kDa subunit or
be an indirect interaction and require other components for stabilizing the 160 kDa
subunit of CPSF. In vitro, CF Im enhances the rate of poly (A) site cleavage, and has
been shown to interact with PAP and PABPN1 via its 25 kDa subunit (41). Furthermore
CF Im also interacts with splicing factors, indicating a role in communicating between
different RNA processing complexes (12).
As mentioned earlier CF Im facilitates multiple interactions among mammalian
mRNA processing members, not only in cleavage and polyadenylation, but also in
splicing. Despite its apparent role in the mammalian system and similarities to the yeast
processing machinery, there is no homolog of CF Im subunits in yeast. However the
strong sequence conservation in higher eukaryotes of the 25 kDa CF Im subunit suggests
CF Im25 may have significant contributions outside of premRNA 3’end processing. In
accordance with this, CF Im25 was confirmed by MALDI mass spectrometry to be
associated as a component of a large RNA complex with Rae1, an mRNA export protein.
This RNA dependent complex was necessary for mitotic spindle assembly and links CF
Im25 with the RNA export machinery (53). This suggests CF Im25 may potentiate other
RNA export processing steps that have yet to be discovered and could be facilitated by
the same interaction surfaces necessary for premRNA 3’end processing.
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The Nudix domain of CF Im25
Biochemical data suggest the 25 kDa subunit of CF Im facilitates many of the key
interactions between CF Im and other processing factors through interactions via the
Nudix Domain of CF Im25. The structural characterization of CF Im25 will allow the
investigation of the function of a Nudix domain present in this protein and validate the
biochemical interactions previously described.
The first Nudix protein to be characterized enzymatically and structurally was
Escherichia coli MutT (54). Nudix proteins are generally characterized as housekeeping
enzymes due to their role in hydrolysis of substrates described as nucleoside diphosphate
linked to another moiety X, many of which are potentially toxic molecules (55, 56).
Nudix proteins have a conserved Nudix fold consisting of an // sandwich (Figure
12). This fold is also common to isopentenyl diphosphate isomerases and the carboxyl
terminus of MutY type DNA glycosylases (55). Within the Nudix fold the consensus
sequence of the Nudix box is GX5EX7REUXEEXGU, where U is a hydrophobic residue
and X is any residue, and folds into a loop   helix  loop structure (54). The glutamate
residues found within this Nudix box are important for divalent metal binding and
catalysis.

The most common bound divalent metal of physiological relevance is

magnesium (56). Members of the Nudix family vary in their substrate specificity,
position of residues involved in substrate coordination, and the number of metals required
for catalysis. In the case of MutT, two divalent ions are necessary for catalysis: one ion

22

is involved in coordination of the substrate to the  and  phosphate, while the second
divalent metal is coordinated by the enzyme (55).
Nudix proteins can recognize and hydrolyze a large range of substrates such as
nucleotide sugars, oxidized and nonmutagenic nucleoside di and triphosphates, RNA
caps, and dinucleoside polyphosphates. Residues and motifs outside of the Nudix box,
which together forms part of the // sandwich of the Nudix domain, determine the
substrate specificity of each Nudix member. Notable differences in substrate binding
exist not only with the recognized substrate, but also with the positioning of the
nucleotide’s base with in the active site (57). The catalytic base is generally a glutamate
residue that can be found within or outside of the catalytic sequence and orchestrates
hydrolysis by substitution at phosphorous (Figure 13) (55).
Nudix proteins are found in a wide range of organisms and likewise have a wide
spectrum of substrate specificities.

This enables them to play a versatile role in

protection, regulation, and signaling. In bacteria, the number of Nudix proteins correlates
linearly with the size of the genome as well as the environmental growth conditions.
Bacteria with a considerably larger genome have more Nudix proteins to promote
genome conservation and allow for the break down of metabolite intermediates found in
harsher environmental conditions (56). This is not consistent in higher eukaryotes where
the genome contains a large amount of noncoding DNA and would result in an
overestimation of Nudix enzymes. To date, the human genome alone encompasses 24
Nudix enzymes and 5 pseudogenes (Table 2).
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Most of the human Nudix enzymes are

found associated with a housekeeping function involving sanitizing the toxic nucleotide
pool with the exception of Dcp2, X29, and CF Im25.
The proteins Dcp2, X29, and CF Im25, all overlap in their ability to bind RNA and
participate in RNA metabolism. Dcp2 functions in the Dcp1/Dcp2 decapping mRNA
complex to generate m7GDP and 5’phosphorylated mRNA. This is an essential function
for 3’ to 5’ and 5’ to 3’ mRNA decay and specialized decay pathways such as nonsense
mediated decay (58). X29 is involved in decapping the U8 snoRNA releasing m7GDP
(56). CF Im 25, unlike both Dcp2 and X29, has no apparent role in mRNA decapping, but
has a function in binding mRNA to facilitate in 3’ premRNA processing events as
mentioned. In addition, it is the only Nudix protein that is associated as a complex with
its counterpart the 59 kDa, 68 kDa, or 72 kDa larger subunit for function in cleavage and
polyadenylation. Interestingly, the Nudix box in CF Im25 lacks two of the four conserved
glutamate residues, three of which were shown to be important for catalysis (59).
Recently, a GDPmannose hydrolase found in enterobacteria and Vibrio species has been
described and similarly lacks two of the conserved glutamate residues of the catalytic
box. This substitution imparts an alternative hydrolase mechanism whereby nucleophilic
substitution occurs at a carbon instead of a phosphorous (Figure 14) (60, 61). This
makes it plausible that CF Im 25 may retain hydrolase activity, albeit with an alternative
substitution mechanism.
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Specific Aims
This project is aimed at elucidating the crystallographic structures of factors
important for premRNA 3’end processing. Currently, there are a limited number of
crystallographic structures of premRNA 3’end processing factors. This ensemble of
structures deposited in the Protein Data Bank include several partial structures and very
few complex structures of processing factors. Crystallographic techniques will allow a
validation of regions important for proteinprotein and proteinRNA interactions that
have previously been reported biochemically. In addition, structural data will provide
insight into new functionally and/or mechanistically important protein residues essential
for premRNA 3’end processing.
The specific processing factor that is the focus of this project is the 25 kDa
subunit of CF Im. CF Im25 is involved in early steps of 3’end processing and contributes
to both proteinprotein and proteinRNA interactions. CF Im 25’s involvement with
multiple factors and with the RNA allows for several candidates for a complex crystal
structure. Interestingly, many of the biochemical interactions with CF Im 25 are
contradictory to each other which made it important to obtain the crystal structures of the
protein alone and in complex with a ligand or protein binding partner to validate the
available biochemical data.
Aim 1 is to crystallize the structure of the apo human CF Im25 protein. The
crystal structure of CF Im25 is expected to provide insight into the function of the Nudix
domain of CF Im25 and its potential role in 3’end processing. The CF Im25 structure is
predicted to harbor the classic Nudix // fold but lacks two of the four glutamic acid
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residues important for catalytic activity and metal binding. The structural investigation
will help further define the domains important for substrate and protein interactions and
elucidate how the structural organization may allow for its versatility in multiple
processing steps. The function and activity of the Nudix domain can be addressed
additionally by biochemical assays. Biochemical assays will be used to determine if
CF Im25 can bind or hydrolyze a nucleotide moiety via its Nudix domain. The outcome
of the previous biochemical data will determine if a nucleotide bound structure is worth
pursuing.
Aim 2 is to determine a complex structure of the 25 kDa subunit of CF Im
(CF Im25) with a binding partner relevant to 3’ premRNA processing. Possible binding
partners of interest are the 68 kDa subunit of CF Im, PAP, and Clp1. Obtaining a
complex of CF Im 25 and its counterpart the 68 kDa subunit will address and validate
which regions of both proteins are necessary to mediate complex formation. Pulldown
assays have previously demonstrated that the RRM of the 68 kDa subunit is sufficient to
bind CF Im 25. Previous data from the literature describing the interaction between PAP
and CF Im 25 are more controversial. The interaction between PAP and CF Im 25 has
been proposed to involve the Nudix region of CF Im25 and a Cterminal truncated PAP.
Additionally, data have been presented that detail this interaction involving CF Im 25 and
the Cterminal region of PAP. Recently, a mechanism has also been described to disrupt
the polyadenylation machinery involving the acetylation at the carboxy terminus of PAP
and amino terminus of CF Im 25. A complex structure of PAP and CF Im 25 will be
necessary to investigate the conflicting biochemical data presented so far. Lastly, a
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structure of the complex between CF Im 25 and hClp1 will be pursued. Clp1p is essential
for yeast premRNA 3’end processing. In humans however, hClp1 plays an important
role in tRNA splicing and as a siRNA kinase but interestingly is not able to complement a
Clp1p knockout in yeast (62). This raises questions about hClp1 importance to 3’end
processing which can be addressed by capturing a complex structure containing CF Im25
and hClp1.
Aim 3 is to determine the crystal structure of hFip1. Recently, hFip1 has been
included as a subunit of CPSF although the stoichiometry of Fip1 to the remaining four
subunits appears to be less than a 1:1 ratio. Despite its transient association with the
other substituents of CPSF, Fip1 is important for the polyadenylation step of premRNA
3’end processing to stimulate PAP. In addition, aim 3 also involves determining a
complex structure of Fip1 with PAP.
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Figure 1: Eukaryotic premRNA 3’end Processing
Eukaryotic premRNA 3’end processing events include capping at the 5’end,
splicesomal cleavage of intronic mRNA, premRNA 3’end cleavage followed by
polyadenylation. These processing events are orchestrated by the recognition of cis
acting sequence elements to recruit processing factors to the site of processing. The
removal of the intronic message allows cleavage factors to be recruited to the mRNA.
Cleavage occurs at a CA dinucleotide as shown and this presents the 3’ end of the pre
mRNA for PAP binding and PABPN1 stabilization for polyadenylation. Adapted from
Danckwardt et al. 2008 (63).
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Factor
CF IA

CF IB
CF IIy

PF 1

Subunit(kDa)
76
72
50
38
73
150
105
100
90
150
105
100
85
64
58
55
53
26

Gene
RNA14
PCF11
CLP1
RNA15
HR P1
YHH1/CFT1
YDH1
YSH1/BRR5
unknown
YHH1/CFT1
YDH1
YSH1/BRR5
PTA1
PAP1
PFS1
FIP1
PFS2
YTH1

a
Ma mm alian Hom ologue

CsfF77


CstF64

CPSF160
CPSF100
CPSF73

CPSF160
CPSF100
CPSF73

poly(A) polym erase

hFIP1

CPSF30

Table 1: Yeast premRNA 3’end Processing components and mammalian
homologues
Yeast premRNA 3’end processing complexes and their individual substituents are
listed, along with their corresponding mammalian homologues. a Mammalian
homologues may exist for additional yeast processing factors but have not been linked to
mammalian processing reactions. This figure was adapted from Wahle et al. 1999 (14).
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Figure 2: Crystal structure of yeast Clp1/Pcf11 bound to ATP
Crystal Structure of yeast Clp1 with Pcf11 fragment (residues 454563) bound to ATP
(PDB 2NP1). The Pcf11 fragment is represented in yellow and the Clp1 protein is
colored according to domain architecture. The Nterminal region of Clp1 is represented
in red and sequesters the ATP within the Central region, colored green. The Central
domain harbors the nucleotide binding motif or Walker A motif. Lastly, the Cterminal
region is represented in blue and shows no structural similarity amongst PDB entries
(20).
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Figure 3: Crystal structure of Pap1 bound to oligo (A)
The yeast Pap1 crystal structure is presented in green bound with a 5mer oligo(A) (PDB
2Q66). In order to capture the RNA bound Pap1 structure aspartate 154 (D154), one of
the catalytic residues, was mutated to an alanine. The remaining catalytic aspartate
residues, D100 and D102, are colored in cyan in addition to the D154A mutation. The
MgATP is not represented for the sake of clarity (25).
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Figure 4: Eukaryotic cleavage components
The core cleavage complex involves the factors depicted above. The recognition of the
conserved hexamer by CPSF160 and additional binding of CstF64 at the downstream
G/U rich element initiates cleavage at the 3’end. Further stabilization at the conserved
hexamer is facilitated by CF Im interactions with CPSF160 and in conjunction with Fip1,
CF Im, recruits PAP to the cleavage complex. Following cleavage complex assembly
endonucleolytic cleavage occurs at the CA dinucleotide.
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Figure 5: Poly(A) tail elongation machinery
Poly(A) tail elongation is facilitated by the factors CPSF, PAP, and PABPN1. PABPN1
is necessary for PAP processivity during tail elongation.
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Figure 6: HAT domain of murine CstF77
Ribbon diagram of CstF77 entire HAT domain shown as a dimer and colored according
to molecule number, molecule 1 (Mol1) is red and molecule 2 (Mol2) is yellow/green.
CstF77 is a dimer in the crystal structure as well as in solution and dimer formation is
mediated through the Cterminal HAT region (PDB 200E). CstF77 HAT domain is
believed to be involved in coordination of proteinprotein interactions (35).
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Figure 7: Structural similarities between CPSF73 and CPSF100
Crystal structures of human CPSF73 and CPSF100 share common folds, both belonging
to the metallolactamase superfamily and additionally composed of a CASP domain
(PDB 2I7V and 2I7X). The metallolactamase domain is represented in cyan and
purple (Metallo), the CASP is shown in pink, and grey spheres represent zinc atoms.
Additional helices are apparent in the Metallo domain colored in cyan and are thought
to be specific to RNA/DNA processing nucleases (42).
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Figure 8: Interaction of the 25kDa subunit of CF Im with PAP513
GSTCF Im25 is able to interact directly with in vitro translated [35S]methionine labeled
full length PAP, Cterminally truncated PAP (PAP513 or PAPC) and PABPN1 via pull
down experiments (41). This evidence contradicts previous data demonstrating the C
terminal region of PAP is necessary to mediate interaction with CF Im25 (64). This
figure was adapted from Dettwiler et al. 2004.
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Figure 9: Crystal structure of bovine PAP513 in complex with 3’dATP
A. Representation of the C, Middle, and N Domains as previously shown in the yeast
Pap1 structure. The arrow indicates the position of 3’dATP (cordycepin). B. The
catalytic triad consisting of aspartic acid 113, 115, and 167 are involved in coordination
of the bound magnesium and 3’dATP (48).
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Figure 10: Scheme of the direct interactions among processing factors
Multiple interactions among polyadenylation premRNA 3’end processing factors are
coupled to splicing and mRNA export (12, 41, 44, 6466).
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Figure 11: Domain architecture of the CF Im subunits
CF Im25 is composed of a Nterminal domain involved in RNA binding interactions, a
nucleoside diphosphate linked to another moiety X domain (Nudix) located centrally, and
a Cterminal domain. The 68 kDa subunit has an Nterminal RNA recognition motif
(RRM) involved in proteinprotein interactions, central prolinerich (Prich) region, and a
Cterminal charged arginine and serine domain reminiscent of SR proteins.
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Figure 12: Signature fold of Nudix proteins
MutT was the first Nudix protein to be characterized and demonstrates the classic //
sandwich of the Nudix fold (2AZW). Within the Nudix fold is the conserved Nudix box
and has the representative sequence. The arrow depicts the position of the Nudix box
(67).
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Figure 13: Mechanism of substrate hydrolysis by Ap4A pyrophosphatase
Mechanism of substrate hydrolysis with nucleophilic substitution occurring at a
phosphorous by the Ap4A pyrophosphatase enzyme from B. bacilliformus. Catalysis of
the substrate, diadenosine tetraphosphate (Ap4A), requires three divalent metals, two of
which are bound by the enzyme (ENZ). This figure was adapted from Xia et al. 2005
(55).
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B

Figure 14: Alternative mechanism of GDPmannose hydrolase
(A and B) Schematic diagram of two possible mechanisms of nucleophilic substitution
occurring at a carbon instead of a phosphorous by the E. coli enzyme GDPmannose
hydrolase. Both mechanisms are based on structural and biochemical data. This figure
was adapted from Bianchet et al. 2004 (68).
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Table 2: Human Nudix genes and hydrolases
Summary of the human Nudix genes and hydrolases, including known pseudogenes. The
characterized hydrolases listed are presented with their recognized substrates. This figure
was adapted from McLennan 2006 (56).
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CONTRIBUTIONS

My contributions to the production of this paper include: protein expression and
purification, crystallization experiments, determination of the oligomeric state, structure
solution, steady state fluorescence experiments, and contribution to the writing of the
manuscript. Dr. Mark Rould contributed to troubleshooting the fluorescence experiments
and helpful suggestions for the refinement of Ap4A. Additionally, Dr. Greg Gilmartin
contributed to helpful discussion on the nucleotide binding properties of CF Im25 and
suggested further experiments to determine how Ap4A binding may play a role in 3’end
processing.
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ABSTRACT
Cleavage Factor Im is an essential component of the premessenger RNA 3' end
processing machinery in higher eukaryotes, participating in both the polyadenylation and
cleavage steps. Cleavage factor Im is an oligomer composed of a small 25 kDa subunit
(CF Im25) and a variable larger subunit of either 59 kDa, 68 kDa, or 72 kDa. The small
subunit also interacts with RNA, poly(A) polymerase, and the nuclear poly(A) binding
protein. These proteinprotein interactions are thought to be facilitated by the Nudix
domain of CF Im25, a hydrolase motif with a characteristic // fold and a conserved
catalytic sequence or Nudix box. We present here the crystal structures of human CF
Im25 in its free and diadenosine tetraphosphate (Ap4A) bound forms at 1.85Å and 1.80Å,
respectively. CF Im25 crystallizes as a dimer and presents the classical Nudix fold.
Results from crystallographic and biochemical experiments suggest that CF Im25 makes
use of its Nudix fold to bind but not hydrolyze ATP and Ap4A. The complex and apo
protein structures provide insight into the active oligomeric state of CF Im and suggest a
possible role of nucleotide binding in either the polyadenylation and/or cleavage steps of
premessenger RNA 3' end processing.
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INTRODUCTION

Premessenger RNA 3’end processing in eukaryotes is a twostep reaction consisting of
endonucleolytic cleavage of the premRNA followed by addition of a poly(A) tail at the
3’ end of the upstream cleavage product (1315). The coupling of these processing
reactions relies on multiple proteinprotein and proteinRNA interactions. The factors
that are necessary and sufficient to reconstitute cleavage and polyadenylation in a
mammalian in vitro system are poly(A) polymerase (PAP), cleavage and polyadenylation
specificity factor (CPSF), cleavage stimulation factor (CstF), cleavage factor Im (CF Im),
cleavage factor IIm (CF IIm) and the nuclear poly(A) binding protein 1 (PABPN1). The
recruitment of the mammalian polyadenylation machinery to the premRNA relies on the
recognition of conserved sequence elements, such as the highly conserved hexamer
AAUAAA recognized by CPSF and a U rich sequence downstream of the cleavage site
recognized by CstF. Additionally a set of UGUA elements, a third sequence element
found upstream of the cleavage site and not as universally conserved, is recognized by
CF Im (27, 28). Upon completion of the processing steps the mRNA can be efficiently
transported out of the nucleus into the cytoplasm. Homologs of CF I subunits are also
found in cDNA databases of Caenorabditis elegans, Drosophila melanogaster, and
plants.

CF Im is an oligomer composed of a small 25 kDa subunit (CF Im25, also referred to as
CPSF5 or NUDT21) and a larger subunit of either 59 kDa, 68 kDa, or 72 kDa (40). The
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three larger subunits share substantial sequence homology. They are encoded on two
different genes and the 72 kDa subunit is a splice variant of the 68 kDa polypeptide. CF
Im can be reconstituted in vitro from the 25 and 68 kDa subunits (40). CF Im, in addition
to having a role in regulation of poly(A) site recognition, is also involved in stabilizing
CPSF at the conserved hexamer, enhances the rate of poly (A) site cleavage in vitro, and
has been shown to interact with PAP and PABPN1 via its 25 kDa subunit (41).
Furthermore CFIm also interacts with splicing factors, indicating a role in communicating
between different RNA processing complexes (12).

Much of what we know about complex formation of processing factors on the premRNA
and its regulation has been investigated biochemically. Structural characterization of
individual and multicomponent processing factors will elucidate the domain interactions
important for the 3’ premRNA processing mechanism that cannot be deciphered by
biochemical means. The structure of the 25 kDa subunit of CF Im (CF Im25) will help
further define the domains important for substrate and protein interactions.

The structure of CF Im25 will also allow us to investigate the function of a Nudix domain
present in this protein. The first Nudix protein to be characterized enzymatically and
structurally was Escherichia coli MutT (54). Nudix proteins are generally characterized
as housekeeping enzymes due to their role in hydrolysis of substrates described as
nucleoside diphosphate linked to another moiety X, many of which are potentially toxic
molecules (55, 56). Nudix proteins have a conserved Nudix fold consisting of an //
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sandwich.

Within the Nudix fold the consensus sequence of the Nudix box is

GX5EX7REUXEEXGU, where U is a hydrophobic residue and X is any residue, and
folds into a loop   helix  loop structure (54). Interestingly, the Nudix box in CF Im25
lacks two of the four conserved glutamate residues, three of which were shown to be
important for catalysis (Figure 15) (59).

In this study we present the crystal structure of human CF Im25 alone and in complex
with diadenosine tetraphosphate (Ap4A). CF Im25 crystallizes as a dimer, which is also
the oligomeric state of the protein in solution. The CF Im25 structure presents the classic
Nudix // fold and harbors residues outside of the Nudix core that could potentiate
ligand binding. Structural and biochemical evidence suggests that CF Im25 binds, but
does not hydrolyze, mono and diadenosine nucleotides.
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MATERIALS AND METHODS

Protein purification
The construction of the plasmid expressing the 25 kDa subunit of human cleavage factor
Im (CF Im) with an Nterminal 6xHis tag was previously described (41). The cDNA of
CF Im25 was subsequently cloned into a Gateway® vector with a dual 6xHismaltose
binding protein (MBP) affinity tag provided by Dr. David S. Waugh (National Cancer
Institute, Frederick, MD) (69). The following primers were used in the polymerase chain
reaction (PCR): 5’ GAG AAC CTG TAC TTC CAG GGT ATG TCT GTG GTA CCG
CCC 3', 5’ GGG GAC CAC TTT GTA CAA GAA AGC TGG GTT ATT AGT TGT
AAA TAA AAT TGA A 3', and 5’ GGGG ACA AGT TTG TAC AAA AAA GCA GGC
TCG GAG AAC CTG TAC TTC CAG3’. CF Im25 (227 amino acids) was then expressed
in Rosetta (DE3) pLysS cells (Novagen) and grown in LB medium for 24 hours at 25°C
following induction with 0.4 mM IPTG. The protein was purified on Nickel NTA beads
(Qiagen), followed by a Tobacco etch virus (Tev) protease cleavage step, and cation
exchange on a Resource S column (GE Healthcare):

Cells were lysed at 4ºC by

sonication in a buffer containing 20 mM TrisHCl pH 8.0, 200 mM NaCl, and a protease
inhibitor tablet (Roche). The lysate was centrifuged at 12,000 x g and incubated with Ni
NTA beads (Qiagen) for 1 hour at 4°C. Protein was eluted with lysis buffer containing
100500 mM imidazole. Pooled fractions were dialyzed into 10% (v/v) glycerol, 20 mM
TrisHCl pH 7.5, and 50 mM KCl. CF Im25 was cleaved from the MBP tag by the
addition of equimolar amounts of Tev protease. MBP and Tev were then separated from
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CF Im25 by elution with a 50 mM1 M KCl gradient at pH 7.5 on a Resource S column
(GE Healthcare). The selenomethionyl protein was produced by inhibiting methionine
biosynthesis in Escherichia coli (70) and purified as described above. Proteins were
concentrated to about 620 mg/ml (Millipore Amicon Ultra15), flash frozen and stored at
80ºC.

Crystallization
CF Im25 crystals were initially obtained with the sitting drop method in a 96well tray
format. Sitting drops were set up with a 925 PC Workstation (Gilson) by mixing 0.6 µl
of protein (16 mg/ml) with 0.6 µl reservoir solution (25% w/v PEG 3350, 0.2 M MgCl2,
0.1 M TrisHCl pH 8.5) (Hampton Research Index Screen, condition 85) and equilibrated
against 160 µl reservoir buffer. Subsequently, crystals were obtained by streak seeding
hanging drops with a protein concentration of 6 mg/ml. Hanging drops were set up by
mixing 1 µl of protein with 1 µl of reservoir solution under the same crystallization
conditions. Trigonal crystals grew to a maximum length of 200 µm in space group P3121
(P3221) with unit cell parameters a = b= 80.11 Å, c = 72.21 Å and  = 120º. There is one
molecule per asymmetric unit with an estimated solvent content of 52%. Crystals of the
complex with Ap4A were obtained with the hanging drop method. The hanging drops
were set up manually by mixing 1 µl of protein with 1 µl of reservoir solution (25% w/v
PEG 3350, 0.025 M MgCl2, 0.1 M TrisHCl pH 7.5). The drops were streak seeded after
a 24 h incubation period. When the crystals reached at least 100 µm, Ap4A at a final
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concentration of 44 mM was added directly to the drop. After six hours the soaked Ap4A
crystals were cryoprotected by the addition of 1 µl of 25% (w/v) PEG 3350 and 50%
(v/v) glycerol to the 2 µl hanging drop prior to flash cooling in liquid nitrogen.

Crystallographic data collection
Multiple wavelength anomalous diffraction (MAD) data were collected at beamline 23
IDD (Advanced Photon Source at Argonne National Laboratory) on a MAR m300 CCD
detector. One complete selenomethionyl MAD data set was collected on one crystal at
the peak, inflection, and highenergy remote wavelengths to a maximum resolution of
1.85 Å. Data were collected at 1.80 Å resolution on the Ap4A complex at beamline
X12B (National Synchrotron Light Source) on a Quantum4 CCD (ADSC) detector. The
data from three Ap4Asoaked crystals were merged to increase redundancy. Diffraction
data were processed and scaled with DENZO and SCALEPACK (71). Data collection
statistics are summarized in Table 1.

Structure determination and refinement
The program SOLVE (72) identified three of the four selenium sites (The Nterminal
methionine is disordered or missing). AutoSHARP (73) was then used for refinement of
the selenium parameters.

The space group was judged to be P3121 and not the

enantiomorphic P3221, based on the map quality and continuity. The phasing information
was then used in RESOLVE (72) for density modification and iterative model building.
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70% of the model was built by RESOLVE. The remaining residues were built manually
using the program COOT (74). Residues 120 and 132135 were omitted from the model
because of poorly defined density.
Iterative rounds of refinement including simulated annealing, energy minimization, and
Bfactor refinement were done with CNS (75). Each refinement round was followed by
rebuilding in COOT. A composite simulated annealing omit map was generated in CNS
to validate the model and build the remaining side chains. Water molecules were added
with CNS and COOT. The quality of the model was evaluated with PROCHECK (76).
All nonglycine residues fall within either the most favored or additionally allowed
regions of the Ramachandran plot. The refined model of the unliganded protein provided
phases to calculate an isomorphous difference Fourier (FoFo) map between the
unliganded protein and the complex with Ap4A (77). The Rcross on amplitudes between
the two data sets is 0.149, indicating good isomorphism between the two crystals. The
resulting map showed clear density for one adenine base and three phosphates of Ap4A.
The complex with Ap4A was refined with CNS (75). The refinement statistics for both
structures are reported in Table 3. Figures were drawn with PyMOL (78).

Oligomeric state determination
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Size exclusion chromatography was performed with a Superdex 75 column (GE
Healthcare).

The protein sample or molecular mass standards were applied to the

Superdex 75 column and eluted with 10% glycerol, 20mM Tris pH 7.5, and 50mM KCl.
Standard proteins (Sigma) were: lysozyme (MW 14.4 kDa), egg albumin (45 kDa),
bovine serum albumin (67 kDa), and the void volume was determined with blue dextran
(GE Healthcare). Dynamic light scattering was also used to confirm the oligomeric state
of CF Im25 (Dynapro, Wyatt). The buried surface area (2,800 Å2) was calculated with
AREAIMOL (79) and with CNS (75) (2,700 Å2).

Hydrolase activity assay
The standard reaction mixture contained 50 mM TrisHCl, pH 7.5 or 8.5, 50 mM KCl, 5
mM MgCl2, 1 mM DTT, 20 M CF Im25, 2 U calf intestinal phosphatase (New England
Biolabs) or 1 U S. cerevisiae pyrophosphatase (Sigma), and 2 mM or 4 mM substrate in a
total volume of 50 l. The putative substrates tested for CF Im25 hydrolase activity
include ATP, Ap4A (Sigma), and m7G (5’)ppp(5’)G cap structure analog (New England
Biolabs). The reactants were combined at 4°C then incubated at 25°C for 30 and 60
minutes. The reaction was terminated by the addition of 250 l of 20 mM EDTA and the
liberated orthophosphate was determined by the colorimetric assay of Ames and Dubin
(80) (54). The limit of detection of this assay is 5 M of orthophosphate.

Fluorescence measurements
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Steady state tryptophan fluorescence was measured with a Quantamaster fluorimeter
(Photon Technology International, South Brunswick, NJ) as described (81) with a
WG320 cutoff emission filter. CF Im25 contains four tryptophans and only three are
built in the structure: Trp148 and Trp149 are within 1015 Å of the active site and Trp139
is located within 20Å of the active site. The fourth tryptophan, Trp13, is located in the
disordered portion of the amino terminus.

The tryptophan emission spectrum was

measured by excitation of the samples at 295 nm and collecting the emitted fluorescence
at 90 to the incident light over the range 300400 nm. The slit widths were set at a
resolution of 1 nm for excitation and 4 nm for emission. Fluorescence measurements of
all protein samples were performed using a microcuvettte with a magnetic stir bar in 20
mM TrisHCl pH 7.5, 50 mM KCl, and 25 mM MgCl2 at 25C for the protein alone and
in the presence of increasing amounts of nucleotide. All fluorescence measurements
were corrected for Raman scatter and background fluorescence and represent experiments
performed in triplicate and then normalized and averaged.

The ATP fluorescence data

were fit with a single hyperbola (y = a*x/(b+x)) with a Kd of 1.53 ± 0.18 mM (1.17 – 1.89
mM at 95% confidence interval). The Ap4A data were fitted with a single hyperbola (y =
a*x/(b+x)) with a Kd of 2.44 ± 0.49 µM (1.46 – 3.43 µM at 95% confidence interval).

Cleavage and Polyadenylation assays
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Lamin RNA substrate was capped and uniformly labeled by SP6 RNA polymerase
transcription of a PCRamplified human DNA. In vitro poly(A) cleavage and poly(A)
addition assays using dialyzed and undialyzed nuclear extract from HeLa cells were
carried out as described previously with the addition of diadenosine tetraphosphate
(Ap4A) in increasing amounts (27). Increasing amounts of Ap4A were added in addition
to stoichiometric amounts of MgCl2.
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RESULTS

Crystal structure of human CF Im25
The original Nterminal Histagged plasmid of human CF Im25 (41) did not express to
high enough levels for structural studies. We therefore inserted the coding sequence of
CF Im25 into a dual HisMBP vector (69). With the resulting expression vector, 1.5 mg of
protein could be purified from 1 L of culture. The structure was solved to a resolution of
1.85 Å by multiple wavelength anomalous diffraction of the selenomethionyl protein
variant.

Residues 21131 and 136227 are visible in the electron density map.

A

complex with Ap4A was also obtained and refined to a resolution of 1.80 Å.

Description of the structure
Human CF Im25 is composed of 227 residues, with a calculated molecular weight of 26
kDa. CF Im25 elutes as a dimer in gel exclusion chromatography with an apparent
molecular weight of ~53 kDa (Figure 16). The dimeric state of CF Im25 has also been
confirmed by dynamic light scattering. In the crystal structure, dimer formation relates
two monomers by a twofold crystallographic axis. The Nudix domain is located in the
middle of the protein and spans residues 77202 (Figure 17). The Nudix fold comprises
two mixed  sheets flanked by two helices (2 and 3). The Nudix box is located in
helix 2 (residues 109131) and the preceding loop. The region immediately preceding
the Nudix domain (residues 2176) folds into two distinct segments: residues 2132 form
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an extended loop structure that projects away from the globular domain of the protein
(residues 120 are not visible in the electron density map).

The extended loop is

stabilized via crystal packing interactions with a symmetry related monomer and this
region, which has been shown to participate in RNA binding, is likely to adopt a different
fold in vivo (41).

Lys23 has previously been shown to undergo acetylation, a

modification which modulates the interaction of CF Im25 with PAP (46). The second
segment of the Nterminal region (residues 3376) contributes two short  strands and a
long helix. Within this region an additional modification, this time phosphorylation, was
reported for Tyr40 (82). We do not see either modification because the protein was
expressed in E. coli. The Cterminal region (residues 203227) is composed of two
helices (4 and 5) and a short beta strand (10) comprising the final four residues.

Structural homologs of CF Im25 were searched with the DALI server (83) and significant
structural homology was found, but only with other Nudix proteins, including
Deinococcus radiodurans DR1025 (Z score = 11.2, PDB ID code 1SJY, (59)), Ap4A
hydrolase (Z score = 10.0, PDB ID code 1KT9, (57)), ADP ribose pyrophosphatase (Z
score = 9.3; PDB ID code 1V8M; (84)) and the mRNA decapping enzyme DCP2P (Z
score = 9.0; PDB ID code 2A6T; (85)). The highest Zscore (33.6 with associated rmsd
of 0.6 Å) was actually that of another crystal structure of CF Im25 for which coordinates
were deposited but had no publication associated with it (Structural Genomics
Consortium, Karolinska Institute; PDB ID code 2CL3).
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Dimer interactions
Dimer formation buries an interface of about 2,700 Å2 (75, 79). The buried surface is
extensive and represents 13% of the surface of the homodimer. The dimer interface is
maintained by approximately 20 residues per monomer, which participate in both
hydrogen bonding and nonpolar contacts. The monomer interactions are facilitated by
the amino terminal extension (residues 2132) and by helix 5, the loop preceding helix
5, helix 6, beta strand 6, the loop linking 6 and 7, and beta strand 10.

The main hydrogen bonding contributions are between the amino terminal extension, beta
strand 6, and beta strand 10. These involve residues Thr32 of chain A and Asp142 of
chain B, Ser220 of chain A and Asn147 of chain B as well as the reverse monomer
interactions. The loop preceding helix 5 and the loop between 6 and 7 contribute to
dimer formation through hydrophobic contacts involving residues Pro159 and Tyr160
from chain A and Tyr202 and Phe199 from chain B.

Additional interactions are

provided by stacking helix 5 from one monomer on to strand 6 of the opposing
monomer in a tailtotail fashion allowing hydrogen bonding between residues in the loop
following helix 5.

These hydrogen bonding interactions include Arg221 and its

symmetry mate and the carboxyl group of Ser220 with Asn147 from the opposing
monomers.
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Metal binding
CF Im25 is missing the second and fourth conserved glutamates of the Nudix box
(residues 124 and 128), which are replaced by a leucine and isoleucine, respectively.
These glutamate residues are very often involved in metal binding (59). We therefore set
out to investigate whether CF Im25 was still capable of binding metal via the two
remaining carboxylates. Although the CF Im25 crystals were obtained in the presence of
200 mM MgCl2, there was no identifiable Mg2+ bound in the electron density map.
Magnesium is a light atom, which is usually not easily identifiable in electron density
maps and can often be mistaken for a water molecule. We therefore used metals that are
more electron dense such as MnCl2 and GdCl3 to identify putative metal site(s) (86).
Mn2+ and Gd3+ present the added advantage that they are anomalous scattering atoms,
which should allow unambiguous identification of metal sites.

We were unable to

identify binding of either metal, regardless of whether the metal was cocrystallized or
soaked into preexisting crystals. Since Nudix enzymes require a divalent cation for
catalysis (54), these experiments suggested that it is unlikely that CF Im25 functions as a
hydrolase. This finding called for further investigation of CF Im25’s binding to potential
substrates (see below).

Enzymatic assays and substrate binding
We next set out to investigate whether CF Im25 binds a substrate. We used three different
methods: a colorimetric assay to measure the release of inorganic phosphate (80), co
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crystallization/crystal soaking with putative substrates, and steady state tryptophan
fluorescence experiments.

A colorimetric assay to measure the release of inorganic phosphate, and thus the potential
hydrolytic activity of CF Im25 on nucleotides, was performed (80).

The following

putative substrates were tested: ATP, Ap4A, and the 7mG(5’)ppp(5’)G cap analog. Ap4A
was chosen because the two enzymes found to be most structurally similar to CF Im25
bind Ap4A (57, 59). ATP and the cap analog were tested because of their prominent role
in RNA processing. The assay indicated that, within the limits of detection of the assay,
none of the putative substrates tested were hydrolyzed.

Although CF Im25 does not seem to possess a hydrolytic activity, it could still bind
nucleotides. Several putative ligands were either cocrystallized or soaked into the
crystals: ATP, GTP, ADP, GDP, diadenosine triphosphate (Ap3A), Ap4A, AMP,
7mG(5’)ppp(5’)G cap analog, NAD+, and GDPmannose. In addition to testing these
nucleotides, which are known substrates for Nudix enzymes, we also attempted to co
crystallize CF Im25 with a 21mer RNA derived from the PAP  cDNA sequence (27, 28).
Of all the putative ligands tested, only Ap4A bound to the crystal (see below). The
original crystallization conditions contained 200 mM MgCl2 and 25% (w/v) polyethylene
glycol (PEG) 3350.

Because nucleotides can precipitate in the presence of high

concentrations of PEG and magnesium (87), care was taken to modify the crystallization
conditions so as to decrease or completely eliminate MgCl2 and therefore lessen the risk
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of the nucleotide precipitating out of solution. Conditions with NaCl or even no salt
could be used in lieu of MgCl2 to grow unliganded crystals. Even when the divalent
cation was omitted from the crystallization solution crystals did not form with any of the
ligands tested (with the notable exception of Ap4A), demonstrating that the lack of
binding was not due to the nucleotide falling out of solution.

Binding studies were then performed employing the intrinsic tryptophan fluorescence
properties of CF Im25. The following Nudix ligands were tested: ATP, GTP, Ap4A,
inositol hexaphosphate (IP6), 7mG(5’)ppp(5’)G cap analog, ADP, and AMP.
Dissociation constants (Kd) measured by titrating the ligand concentration were estimated
for ATP and Ap4A (Figure 18A and 18B, respectively). The ATP data were fit with a
single hyperbola curve, indicating one binding affinity with a Kd value of 1.53 ± 0.18
mM. The Ap4A binding data were fit to a single hyperbola curve and represent one
binding site per monomer, resulting in a Kd of 2.44 ± 0.49 µM.

Complex of CF Im25 with Ap4A
Cocrystallization experiments were performed in order to resolve the ligand binding
interactions of CF Im25. Of all the molecules screened only Ap4A was captured in a co
crystal (Figure 19A). The Ap4A cocrystal structure was determined by using the phases
from the unliganded structure. The resulting unbiased isomorphous difference Fourier
(FoFo) map revealed distinct density for one of the adenine bases and three of the four
phosphates of Ap4A, in the cavity of CF Im25 (Figure 19B). The rmsd between the bound
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and apo structures is low (0.41 Å), indicating that only very small changes take place
upon substrate binding (75). The binding site residues Arg63, Arg150, Gln157, and
Lys172 are found outside of the Nudix box region, within 3 Å of the triphosphate moiety,
and are involved in coordinating the triphosphate moiety (Figure 19B). The binding site
is composed of residues from helix 1, beta strand 6, the loop linking 6 and 7, and
beta strand 7. In CF Im25, Arg63 and Arg150 are highly conserved across species while
Gln157 and Lys172 are moderately conserved. The majority of hydrogen bonding
interactions with Ap4A involve the oxygens of the  and  phosphates. The ordered
adenine base of the Ap4A molecule stacks with Phe103, a residue contained within the
Nudix domain. We note that the position of the  phosphate of Ap4A coincides with the
position of a sulfate ion reported for CF Im25 (Structural Genomics Consortium,
Karolinska Institute; PDB ID code 2J8Q).

CF Im25 has a core structure similar to that of the D. radiodurans Nudix protein DR1025
(59) (PDB ID code 1SU2) (Figure 20). Variations between these two structures arise
from an extension in the loop linking 6 and 7, a shortening of the loop following 4
and an additional helix (helix 1) in the CF Im25 structure. The additional helix in
CF Im25 plays a role in sequestering the substrate binding pocket from solvent exposure.
When comparing the positions of the bound nucleotides between CF Im25 and DR1025
we also see variations in substrate fit. Superposition of the ATP bound in DR1025 on to
the CF Im25 structure shows that both the base and phosphate tail would clash with
protein residues in helix 1 and beta strand 5 in the CF Im25 structure (Figure 21).
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Commonly, variations in the nucleotide binding region of Nudix proteins occur due to
differences in the side chains and motifs and contribute to the substrate specificity of the
Nudix protein. Interestingly, both DR1025 and CF Im25 stabilize the adenine base via
stacking interactions with a phenylalanine residue found outside of the Nudix box region.
Base stacking interactions via a Tyr or Phe located 17 amino acids downstream of the
Nudix box is commonly found in all of the Nudix Ap4A hydrolases, including DR1025
(56). Phe103 stabilizes the adenine base in the Ap4A bound CF Im25 structure but is
located six residues upstream of the Nudix box region.

Chelation Affect of Ap4A
Poly(A) cleavage and addition reactions were carried out in the presence of increasing
amounts of Ap4A to investigate the potential role Ap4A in premRNA 3’end processing.
Poly(A) cleavage and addition assays were conducted with lamin RNA substrate and
increasing concentrations of Ap4A or ATP from 0.625mM – 5mM.

Both assays

demonstrated a decrease in 3’end processing at the concentration of 1.25mM Ap4A or
ATP. This inhibition of processing could be alleviated by the stoichiometric addition of
MgCl2 and demonstrates the mechanism of inhibition is via chelation of catalytically
important metals (Figure 22). This suggests that if Ap4A does play a role in 3’end
processing events it can not be deciphered by utilizing the in vitro decoupled cleavage
and poly(A) addition assays.
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Electrostatic surface and putative RNA and protein binding regions
The electrostatic surface potential of CF Im25 was calculated with GRASP (Figure 23A)
(88). The amino terminal region and residues 78160 of the Nudix domain were shown
to participate in RNA binding (7). We observe a good correlation between the location of
the putative RNA binding residues and that of the positively charged residues on the
surface of the protein (Figure 23B).
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DISCUSSION
In our crystal structure CF Im25 is a homodimer. A dimeric state for CF Im25 is consistent
with dynamic light scattering (DLS) and gel filtration experiments performed with the 25
kDa subunit both unliganded and with ATP or Ap4A. The dimeric structure of CF Im25
suggests that the active form of CF Im may be a heterotrimer composed of a CF Im25
homodimer and either the 59 kDa, 68 kDa, or 72 kDa subunit. This is consistent with
interaction studies in C. elegans (DIP interaction database accession DIP:25083N) where
the CF Im25 homolog (Uniprot accession Q93716) was found to interact with itself and
with the CF Im68 homolog (Uniprot accession Q18937). Alternatively, the complex with
the larger subunit of CF Im could be a heterotetramer. A third possibility is that CF Im25
monomerizes upon binding the larger subunit.

The Nudix box of CF Im25 lacks two of the four glutamates important for catalytic
function and metal binding. Our structural and biochemical characterization suggests that
CF Im25 is able to bind but not hydrolyze nucleotide substrates.

In the dinucleotide

bound CF Im25 structure, the dinucleotide is found outside of the Nudix box and lies
deeper within the active site compared to ATP in DR1025. The fluorescence binding data
for CF Im25, indicate a binding affinity in the low micromolar range for Ap4A indicative
of a potential role as a signaling molecule and a weak, albeit physiologically relevant,
binding affinity for ATP. Even though CF Im25 binds both Ap4A and ATP, we have so
far only been able to obtain a cocrystal complex with Ap4A. It is entirely possible that
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the crystallization conditions we have explored to date for the proteinATP complex are
not compatible with the formation of a crystal lattice and that further exploration of the
crystallization space might yield the desired conditions. We note that preformed crystals
of CF Im25 dissolve upon addition of ATP, indicating a possible conformation change
upon binding of the nucleotide.

To our knowledge, CF Im25 is the first example of a Nudix protein binding and not
hydrolyzing a nucleotide substrate. This loss of function/gain of a regulatory role is not
unprecedented in evolution. A similar loss of function was reported for the Lactobacillus
lactis ATP phosphoribosyl transferase (ATPPRT) regulatory subunit, His Z (89). ATP
PRT functions to initiate the biosynthesis of histidine and requires both the HisZ subunit
and HisG, the catalytic subunit, for activity. The regulatory subunit, HisZ, resembles the
catalytic domain of functional histidyltRNA synthetases (HisRS) and utilizes its fold, not
for catalysis, but for binding of histidine to monitor histidine levels. Although there were
no metals evident in either the free or bound structures of CF Im25 and no identifiable
hydrolytic activity in our colorimetric assay it remains possible that the Nudix box of CF
Im25 could potentiate hydrolysis of Ap4A and ATP upon interaction of CF Im25 with one
of the larger CF Im subunits or additional binding partners. Subsequent in vitro poly(A)
cleavage and addition assays in the presence of Ap4A suggests a possible role in
processing maybe more evident with a reconstituted cleavage and poly(A) addition
reaction. A reconstituted system would allow addition of only the components necessary
for both the cleavage and polyadenylation assays. Alternatively, this result could suggest
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CF Im25’s binding specificity is related to an alternative function outside of premRNA
3’end processing and additionally may validate a loss of function model.

Ap4A belongs to the family of diadenosine oligophosphates, ApnA, which were first
discovered forty years ago (90, 91). Ap4A is composed of two adenosines and four
phosphates linked in 5’ to 5’ phosphodiester linkages. The role of ApnAs in higher
eukaryotes has remained elusive. Recently, ApnAs have been suggested to play a role as
putative extra and intracellular signaling molecules. Ap4A itself is involved in the
cellular stress response, inhibition of KATP channels, stimulation of DNA replication and
repair, as well as influencing other essential cellular processes in eukaryotes (90, 91).
Presently, the only link between Ap4A and 3’end processing was described in yeast
where stimulation of primer independent synthesis by yeast poly(A) polymerase was
observed in the presence of dinucleoside polyphosphates, including Ap4A (92). There is
no CF Im25 homolog in yeast but this observation still suggests a potential role for
dinucleoside polyphosphates as signaling molecules during RNA processing events. The
concentration of ATP and Ap4A can fluctuate within the cell in response to cellular stress
or growth. Preliminary experiments on the role of Ap4A during the polyadenylation step
of 3’ end processing resulted in a noncompetitive inhibition of polyadenylation in a poly
(A) extension assay with mammalian PAP (results not shown). This suggests that under
conditions of high concentrations of Ap4A such as stress, Ap4A can bind to a site in PAP,
other than the ATP binding site, to inhibit polyadenylation.
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The residues 81160 of the Nudix domain play a dual role, binding RNA and stabilizing
proteinprotein interactions. Additionally, the amino terminus (176) participates in RNA
binding (Figure 2) (41). A stable interaction between CF Im25 and CF Im68, unlike that
involving PAP or PABPN1, requires the entire CF Im25 protein. CF Im68 must contact
regions outside of the known RNA binding region of CF Im25 to promote complex
formation and stimulate premRNA 3’ end processing. Interestingly, CF Im25 has a patch
of negatively charged surface residues that runs the length of the dimer interface (Figure
7A). This charged region is composed of residues primarily from beta strand 3 and
helix 4 and could potentiate proteinprotein interactions with CF Im25’s other binding
partners, possibly CF Im68. Also intriguing is the observation that a binding interaction
between the substrate RNA and the 25 kDa subunit occurs in the absence of a putative
RNA binding domain. This suggests another mechanism of RNA recognition, possibly
through homodimer formation.

A CF Im25 homodimer may enhance the binding

potential to the RNA substrate compared to a monomer interaction by increased surface
area interactions. A definite answer regarding the oligomeric state of the 25 kDa subunit
and the RNA binding mechanism will have to await a CF Im25 structure with RNA
bound.

The results reported here suggest that CF Im25 is unable to hydrolyze nucleotides or
dinucleotides even though it harbors a classic Nudix fold. The Nudix domain of CF Im25
may instead facilitate proteinprotein interactions, as suggested by the large distribution
of charged residues in the electrostatic surface representation of the Nudix domain. This
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charge distribution of the Nudix domain correlates well with results from pulldown
experiments with PAP and PABPN1 (41).

The interaction of CF Im with the RNA substrate and with PAP stimulates the rate of
polyadenylate tail synthesis. This may be facilitated by the binding of ATP to CF Im25.
Preliminary data (S. Dettwiler and W. Keller, unpublished) showed that CF Im25 interacts
with hClp1, a protein shown to bind ATP which is involved in 3’ premRNA processing
and tRNA splicing (20, 93). This observation, in conjunction with the fact that hClp1 has
recently been shown to function as an siRNA kinase and a kinase that phosphorylates the
5’ end of the 3’ splicing product in human tRNA splicing (94), suggests a possible link
between CF Im25’s binding of ATP and proteinprotein cross talk. Recently, CF Im25 has
also been shown to be associated in a large RNP complex with Rae1, an mRNA export
protein, in the nucleation and stabilization of microtubules during spindle assembly (53).
This interaction is via CF Im25 association with an RNA component of the RNP complex
and suggests a role for CF Im25 in mRNA export via direct RNA association that may be
influenced by the concentration of intracellular nucleotides or dinucleotides.
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Figure 15: Sequence alignment of CF Im25 with Nudix proteins
ClustalW sequence alignment of CF Im25 and Nudix proteins of known structure (95).
PDB ID codes are shown to the right of the enzyme names followed by the residue
number of the first amino acid. The position of the Nudix box is indicated below the
alignment as a grey/black bar where the black part marks the position of helix 2.
Residues are on a light blue background if over 70% conserved or hydrophobic or
hydrophilic and are on yellow background if invariant. The two catalytic glutamates
conserved in most Nudix enzymes are displayed in red font on light orange background.
L124 and I128, which are found in place of the conserved glutamates, are boxed in the
CF Im25 sequence. The abbreviations are defined as: PPHase for pyrophosphohydrolase
and PPase for pyrophosphatase.
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Figure 16: Gel filtration profile of CF Im25
Gel filtration profile of CF Im25 corresponding to an estimated molecular weight of
53 kDa. Vo is the elution volume of the blue dextran. Proteins were loaded onto a
Superdex 75 gel filtration column (GE Healthcare), and protein elution was followed at
A280 nm. The elution volume of protein standards (bovine serum albumin, 67 kDa; egg
albumin, 45 kDa; lysozyme, 14.4 kDa) and blue dextran is indicated on top of the graph.
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Figure 17: Domain organization of CF Im25
Ribbon diagram of the CF Im25 dimer comprising residues 21131 and 136227. The
ribbon color scheme corresponds to that of the domain architecture shown below. The
second monomer on the left is shown in light grey. The secondary structure numbering is
based on a DSSP analysis (96).
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Figure 18: CF Im25 steady state tryptophan fluorescence experiments with ATP and
Ap4A
All data are represented as normalized and averaged experiments done in triplicate. Error
bars that are not represented lie within the symbol.
A. ATP steadystate tryptophan fluorescence data are fit with a single hyperbola, with Kd
= 1.53 mM.
B. Ap4A steadystate tryptophan fluorescence data are fit with a single hyperbola, with
Kd = 2.44 µM.
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Figure 19: Complex of CF Im25 and diadenosine tetraphosphate
A. The arrow points to the position of Ap4A within the CF Im25 dimer shown rotated
120° as compared to Figure 2.
B. The ordered moieties of Ap4A (adenine base and triphosphate) are superimposed on
an original, unbiased 1.80Å (FoFo) isomorphous difference Fourier map contoured at
2.6 (cyan) and a simulated annealing omit map contoured at 2.7 (magenta). The
adenine base of CF Im25 is stabilized through base stacking interaction with Phe103.
Arg63, Arg150, Gln157 and Lys172 contact the oxygens of the  and  phosphates.
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Figure 20: Comparison with other Nudix proteins
A. Superposition of the Nudix regions between DR1025 (PDB ID code 1SU2) (59) and
CF Im25 in their monomeric form. The superposition was calculated over residues 12
145 in DR1025 and 77202 in CF Im25. DR1025 is shown in light green and its bound
substrate (ATP) is colored in red. CF Im25 is colored according to its domain architecture
as shown in Figure 2.
B. Sidebyside representation of the monomeric forms of the substrate bound DR1025
and CF Im25 with ATP from the DR1025 structure and the conserved glutamate residues
both shown in red.
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Figure 21: Positions of DR1025 ATP and Ap4A in the CF Im25 structure
Positions of the DR1025 ATP shown in red and CF Im25 Ap4A colored in orange
(phosphates) and blue/green (adenine base) within the CF Im25 structure. Ligand position
was determined by superposition of the Nudix region over residues 12145 in DR1025
(PDB ID code 1SU2) and 77202 in CF Im25. Only one CF Im25 monomer is shown.
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Figure 22: Poly(A) assays in the presence of additional nucleotide
Polyadenylation assays are presented with increasing amounts of either ATP or
magnesium (Mg) with a triangle and constant or in addition to amounts, are presented by
+/. The addition of Ap4A or ATP inhibits poly(A)adenylation, but can be restored by
stoichiometric amounts of Mg.
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Figure 23: Surface representation of CF Im25
A. Electrostatic potential surface representation of dimeric CF Im25 calculated by the
program GRASP (32). The surface is shown in the same orientation as in Figure 2 (left)
and rotated 90° (right). The surface on the right was made semitransparent to show the
bound Ap4A (shown with arrow). The areas of negative charge are depicted in red,
whereas the positively charged regions are colored in blue.
B. Ribbon diagram of dimeric CF Im25 in the same orientation as in A. with residues 21
160 corresponding to the RNA binding region highlighted in green.
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Table 3: Data Collection and Refinement Statistics
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CHAPTER 3:
Crystallization Trials of CF Im25 with
Various Binding Partners
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Introduction: CF Im
CF Im is recruited early to the premessenger RNA during premRNA 3’end
processing to assemble the cleavage complex. Additionally, CF Im has been shown to
regulate poly(A) site recognition by binding UGUANcontaining sequence elements in
the vicinity of the poly(A) site (27). The binding of CF Im to UGUANcontaining RNA
sequences suggests an additional mechanism to select for noncanonical hexamer
sequences and alternative poly(A) sites. This has subsequently been demonstrated by the
recognition by CF Im of human poly(A) sites lacking a conserved hexamer in a sequence
specific manner (28). The recent crystal structure of CF Im25 validates previous
biochemical research regarding the RNA binding region and potential regions thought to
be involved in proteinprotein interactions with alternative processing factors. In
addition, the recent finding that CF Im25 is a dimer both in solution and in the crystal
suggests an alternative stoichiometry of CF Im than previously described (97). The CF Im
complex contains a dimer of the smaller 25 kDa subunit and a monomer or dimer of
either the 59 kDa, 68 kDa, or 72kDa larger subunit.
The stoichiometry of the CF Im complex can be further investigated
crystallographically by the pursuit of a complex structure containing the 25 kDa subunit
and the 68 kDa subunit. Additionally, obtaining a complex of CF Im bound to a UGUAN
containing sequence will investigate CF Im’s regulation of premRNA 3’end processing
events by recognition of UGUANcontaining RNA.
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Proteolytic Degradation Occurs at the Cterminal Region of CF Im68
Initial attempts to express and purify the CF Im components involved expression
in insect cells and purified using a dual baculovirus vector. The dual vector allows for
the expression of cDNA for both the 68 kDa and 25 kDa CF Im subunits. The complex
was purified following expression using two chromatographic steps: CF Im components
were purified away from insect cell lysate using NiNTA and anion exchange
chromatography techniques. The eluted protein following the anion exchange column
had a multiple banding pattern visible by SDSPAGE at the apparent molecular weight of
the 68 kDa subunit. This banding pattern increased over time and was thought to be due
to the degradation at the Cterminal region of CF Im68. The Cterminal region is
predicted to be disordered by disorder prediction programs such as PONDR and Poodle
(23, 98) making it a likely candidate for proteolytic degradation (Figure 24). The 68 kDa
subunit of CF Im is composed of an amino terminal RRM, central proline rich region, and
a carboxy terminal alternating arginine/serine region (RS). We expected the amino
terminus of the 68 kDa to be resistant to proteolysis due to the presence of CF Im 25
during our purification because of previously described interactions between the 68 kDa
RRM region and CF Im25 (41). The degradation of the 68 kDa Cterminal end was
confirmed by Western blot analysis using an antibody which recognized the amino
terminal hexahistidine tag of the 68 kDa subunit. The Western blot exhibits the similar
banding pattern seen on the SDSPAGE gel indicating degradation of the Cterminus of
the 68 kDa subunit. Additionally, the protein complex required a concentration step prior
to setting up crystallization screens to obtain a millimolar protein concentration range
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suitable for crystallization. This process resulted in the precipitation of CF Im at
concentrations higher than 2 mg/ml. Stabilization of CF Im could not be achieved by
adjusting the salt concentration or the buffer pH as demonstrated by a greater than 20%
polydispersity in Dynamic Light Scattering (DLS) experiments (Figure 25).
Crystallographic screens were still attempted with the CF Im complex despite the
heterogeneity of the CF Im68 Cterminal region and poor solubility of CF Im at high
protein concentrations.

UGUAN Containing RNAs do not Stabilize CF Im
Recombinant CF Im has been shown to bind with high affinity to UGUAN
containing RNAs as demonstrated by SELEX analysis (27). In this manner a UGUAN
containing RNA can be used to stabilize the degradation at the Cterminal region of the
68 kDa subunit and allow for a stable complex suitable for crystallization. To utilize this
technique crystallographically a UGUANcontaining RNA of minimal length and bound
by CF Im was first investigated by electromobility shift assays (EMSA). CF Im’s ability to
bind the short UGUANcontaining RNA by EMSA was compared to the 60mer SELEX 1
RNA to determine binding potential (27).
CF Im was unable to form a stable complex in gel shift experiments utilizing short
UGUAN containing RNAs from the 3’UTR of PAP gamma and 3’UTR of PAP alpha.
However, both a 20mer and a 40mer oligo, whose design was based on the SELEX 1
sequence, demonstrated weak binding in comparison to a high affinity shift seen with the
60mer SELEX RNA. Improvements to the shifting potential of CF Im were not achieved
86

with changes in the gel shift conditions. Therefore, having found two RNAs capable of
forming a complex with CF Im, albeit weak in comparison to the 60mer SELEX RNA,
crystallization trials were initiated. However as mentioned previously this requires
concentration of the protein sample prior to setting up crystallization screens. The short
SELEX RNAs were included in the concentration step with the hope of increasing the
protein solubility. As seen previously, CF Im precipitated out of solution at high
concentrations regardless of the presence of RNA, confirming CF Im cannot be stabilized
by the addition of RNA to achieve high protein concentrations necessary for
crystallographic screening.

Complex Crystallization Attempts with CF Im25 and 68 kDa Truncation Mutants
Prior attempts to crystallize CF Im as a complex alone or in the presence of RNA
were unsuccessful due to protein solubility issues at high concentrations. This led us to
focus on a minimum complex crystal structure containing the CF Im25 subunit and the
minimal region of the 68 kDa subunit necessary to maintain complex formation. Two 68
kDa truncation mutants, the 68 kDa RRM (68RRM) and the 68 kDa Nterminus (N68),
were investigated for on their capacity to interact with the 25 kDa subunit (41). The
68RRM retains only the RRM region, (81160) necessary to facilitate proteinprotein
interactions with premRNA 3’end processing factors including CF Im25. The N68
construct contains amino acids 1160 representing the Nterminal region in addition to
the RRM (Figure 26). It should be noted that both constructs lack the RS region and
therefore are unable to interact with RNA (41).
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The N68 construct was a primary focus due to its ability to maintain an interaction
with CF Im25 while encompassing the amino terminal region. The complex association
and stoichiometry between the N68 mutant and CF Im25 was evaluated using DLS and
gel filtration experiments. Gel filtration experiments showed separate elution profiles for
the N68 and CF Im25 when combined at equal millimolar concentrations (Figure 27).
Additionally, the N68 construct with an empirical molecular weight of 17.6 kDa elutes
prior to CF Im 25 suggesting an oligomeric state for the N68. Further assessment of the
oligomeric state of the N68 by DLS also suggests an aggregated state represented with a
high polydispersity and molecular weight. The high polydispersity of N68 cannot be
resolved by addition of CF Im 25 in a ratio of 1:1 or 1:2 as evaluated by DLS or upon
addition of CF Im25 and Ap4A (Figure 28). Crystallization trials were attempted,
although the N68 and CF Im25 did not demonstrate a stable complex by either gel
filtration or DLS. Attempts were made under the assumption that a high concentration
suitable for crystallization may drive complex association.
Along with the N68 characterization, the 68RRM construct was expressed and
purified. This construct did not yield much protein suitable for crystallization trials and
attempts to improve the expression and purification were not successful. Despite the low
protein yield, 68RRM/CF Im25 complex crystallization trials were preformed. Several
crystallization conditions were screened and a single crystal was obtained with N68/CF
Im25 that did not diffract. Effort to improve the crystal conditions by varying the
precipitant concentration and pH were not successful.
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Conclusions
The CF Im complex can be reconstituted in vitro with the 25 kDa subunit and the
68 kDa subunit. The interactions between the two subunits is via the RRM region of CF
Im68 and the Nudix region of CF Im25 (unpublished data (41). The CF Im25 protein is
represented both in the crystal structure and in solution as a dimer with a large dimer
interface suggestive of a CF Im complex containing a dimer of CF Im25 and a monomer or
dimer of the 68 kDa subunit. Attempts at addressing complex formation
crystallographically with the both fulllength constructs of CF Im25 and CF Im68 were not
successful. This was certainly due to degradation at the Cterminal region of the 68 kDa
subunit and protein solubility problems at high protein concentrations that could not be
resolved by the addition of RNA. Increased stability between the two subunits was seen
with a larger RNA substrate as suggested by the stable interaction with the SELEX 60
mer RNA in EMSA experiments. However, this RNA length presents problems during
crystallization trials due to unbound regions that may remain flexible and hinder crystal
packing. Analysis of the secondary fold of the UGUANcontaining RNAs suggests a
secondary structure representing a hairpin fold where structure complexity increases
based on length of the RNA (Figure 29). This suggests the shorter RNA may not have
the secondary structure complexity necessary for CF Im complex recognition.
Pursuit of a minimal crystal structure containing the CF Im25 with two different
CF Im68 Nterminal region constructs was also not successful. Inability to obtain a
diffracting complex crystal was impeded by poor expression and purification of the
68RRM and inability to optimize crystal conditions for the complex containing the N68
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construct. In general, RRM domains have a rigid fold making them suitable candidates
for crystallographic trials. The inability to obtain a crystal utilizing this construct
suggests more crystallization conditions need to be screened. To do so requires
improvement of the expression and purification system by cloning the RRM construct
into a better optimal expression vector.
The N68/CF Im25 complex yielded a crystal that did not diffract, could not be
used for seeding techniques, and whose conditions could not be improved (Figure 30).
These results suggest that the Nterminal residues 180 of the 68 kDa are not well ordered
in comparison to the RRM region. In agreement with this, secondary structure
predictions of CF Im68 place the Nterminal residues within the disordered regions of the
plot. Although CF Im25 has been shown to interact with the RRM region of CF Im68 this
interaction does not encompass the additional Nterminal amino acids 180 and alone
these residues do not fold into a rigid structure suitable for crystallization.
To conclude, obtaining a complex structure of CF Im relies on optimizing the
expression and purification of the 68RRM and additionally, it may be necessary to
include other premRNA 3’end processing components in hopes of stabilizing subunit
interactions.

Introduction: CF Im25 and PAP
CF Im25 is recruited early to the premRNA to recruit, stabilize, and regulate pre
mRNA 3’end processing by facilitating multiple proteinprotein interactions. One such
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interactions includes the proposed binding of CF Im25 with poly(A) polymerase (PAP),
which can be described as controversial given the opposing biochemical data available.
Initial findings by Kim et al. 2001 describe a minimal interaction between murine PAP
and CF Im25 comprising the Cterminal 69 residues of PAP and Nterminal 60 residues
of CF Im25, in the absence of RNA (64). Similar domain interactions have recently been
characterized involving modifications to the Cterminal region of PAP and Nterminus of
CF Im25. Acetylation of lysines 635/644/730/734 of PAP and lysine 23 of CF Im25
disrupts the 3’end processing machinery indicating that acetylation can regulate pre
mRNA 3’end processing (46). In contrast, a Cterminally truncated PAP (PAP513) was
shown to still maintain interaction with CF Im25 in pulldown assays (Figure 31 and 32)
(41). This discrepancy can be investigated biochemically by determining the oligomeric
state of the complex and crystallographically by obtaining a complex crystal structure of
PAP513 and CF Im25.

A Stable Complex is not Maintained by Gel Filtration Chromatography
The stoichiometry and oligomeric state of the CF Im25 and PAP513 complex can
be evaluated by both gel filtration experiments and DLS. As mentioned previously,
CF Im25 forms a stable dimer in solution and is expected, based on the large dimer
interface, to maintain dimerization upon binding other 3’ processing components (97).
Investigation of the estimated molecular weight of the complex by gel filtration
experiments was determined by varying the protein ratio of CF Im25 to PAP513.
Complex association was performed with an excess of CF Im25 in order to obtain a
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complex with either a 1:1 or 1:2 stoichiometry off the gel filtration column. The elution
profile estimates the molecular weight of the complex to be 80 kDa on a Superdex 200
gel filtration column (GE Healthcare). The elution of CF Im25 alone yields an apparent
molecular weight of 95 kDa on the same column, which encompasses a wide molecular
weight range and is therefore less exact at low molecular weights. This finding suggests
the overlap in the elution profile may represent the coelution of the individual proteins
based on a similar molecular weight of 58 kDa for PAP and 52 kDa for a dimer of
CF Im25. This hypothesis can be further explored by observing the elution profile of
CF Im25 alone and the complex on a Superdex 75 column (GE Healthcare). The
Superdex 75 has a narrower molecular weight range and therefore should represent a
better estimate of the individual proteins molecular weight versus a complex molecular
weight. The estimated molecular weight of the CF Im25 dimer is 51 kDa and the complex
elutes at approximately the same position indicating that both CF Im25 and PAP are co
eluting based on their individual apparent molecular weights. Furthermore, the addition
of ATP or Ap4A did not shift the elution profile to a larger molecular weight indicative of
a complex formation.
Complex formation can be evaluated by dynamic light scattering experiments,
which can also provide an estimate of the oligomeric state of each protein in solution. CF
Im25 and PAP513 incubated in a 2:1 ratio display a polydispersity in the range of 25%
and a molecular weight of 8090 kDa over a temperature range of 5C  25C.
Interestingly, the DLS intensity reading for the complex is unexpectedly low for a
solution at 0.4 mg/mL concentration, suggesting that precipitation might have occurred
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during sample preparation. Despite possible sample preparation issues, the DLS results
complement the gel filtration data and imply that the interaction between the two proteins
is not direct, the interaction involves a monomer of CF Im25 with PAP513, or the
experimental conditions are not suitable to maintain a complex interaction.

Complex is Stabilized during Electromobility Shift Assay
The CF Im25 and PAP513 complex association was additionally addressed using
electromobility gel shift assays (EMSA). Incubation of PAP513 with CF Im25 in the
presence of 32P ATP resulted in a slight supershift when compared to PAP513 alone
(Figure 33). This experiment was performed once and should be repeated to confirm the
supershift. This finding, however, suggests that CF Im25 can interact with PAP and does
so in the presence of ATP but provides little information on stoichiometry or affinity.

Crystallization Attempts of the CF Im25/PAP513 Complex
Crystallization trials of the CF Im25 and PAP513 complex were set up at a 1:1 and
2:1 protein ratio and concentrated to approximately 3 mg/mL. In addition to
crystallization trials of the complex alone, CF Im25 and PAP513 were incubated with a
nucleotide or nucleotide moiety to stabilize putative flexible binding regions. CF Im25
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and PAP513 were eluted over a gel filtration column following complex incubation with
ATP, Ap4A, or 3’dATP. The eluted fractions were pooled individually based on the
stoichiometry estimated by the staining intensity on an SDSPAGE and concentrated. A
complex was also attempted using a PAP513 mutant crosslinked to a 15mer oligo(A).
The crosslink is made via an alanine to a cysteine mutation on residue 152. The PAP
mutant, in addition to the mutation of the crosslinking residue, has all cysteines mutated
to serines with the exception of residue 118 and 204, which are mutated to valines.
Possible complex crystals of CF Im25 and the crosslinked PAP/RNA were
obtained in several of the conditions from the Hampton Peg Ion Screen (Hampton
Research). The crystals had a similar morphology to PAP513 crystals, resembling
needles and the calculated volume of either a 1:1 or 1:2 complex crystal would be
permitted in the orthorhombic space group of PAP513. To verify the crystal contained
both CF Im25 and PAP, the crystals were dissolved and run on an SDSPAGE gel. The
presence of only the crosslinked PAP on the gel confirmed the crystal did not contain a
complex. Additionally, the crosslinked PAP/RNA was also able to crystallize in these
conditions alone. One other crystal was obtained from the incubation of CF Im25,
PAP513, and Ap4A in the condition 0.1M sodium iodide, 28% (w/v) PEG 3350, and 10%
(v/v) glycerol. This crystal did not diffract, did not produce crystal seeds following a
liquid nitrogen thaw into similar conditions, and could not be reproduced.
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Conclusions
The above results concerning the CF Im25 and PAP513 complex confirm that
these proteins are able to interact and this interaction can be facilitated in the absence of
the Cterminal region of PAP. However, there are still many unanswered questions
regarding the stoichiometry of the complex and complex affinity that were not verified by
DLS or gel filtration experiments. The gel filtration and DLS results provide evidence
both for and against complex association. Results show a possible complex may be
composed of a monomer of CF Im25 and a monomer of PAP513 or the apparent
molecular weight is reflective of the coelution of the individual proteins, CF Im25 as a
dimer and PAP as a monomer. The complex association and affinity of the complex may
be regulated by the presence of a nucleotide and/or substrate, such as RNA. This
regulation could be reflective of the events during 3’end processing where a weak
interaction is apparent when processing components or substrates are absent. A direct or
high affinity binding may additionally involve the Nterminal region of CF Im25 and the
Cterminal of PAP and explain why modification of these regions by acetylation results
in disruption of the processing machinery.
In order to obtain a complex consisting of both CF Im25 and PAP513 it may be
necessary to determine the binding affinity in the presence of nucleotide or substrate via
gel shift experiments. This could identify a high affinity state that could then be pursued
crystallographically. An attempt at obtaining a complex may also be successful with
additional 3’end processing components to further stabilize CF Im25 and PAP. The
interaction of CPSF160 with PAP has been demonstrated to be important in PAP
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stimulation in addition to the functions of Fip1 and CF Im suggesting CPSF160 may be a
suitable candidate (44).
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Introduction: Fip1
Factor Interacting with Pap1 (Fip1) was identified as the fifth subunit of CPSF
and in conjunction with CPSF160, Fip1 plays an essential role in the recruitment of PAP
to the poly(A) site (44). PAP binding to the premRNA is relatively weak and nonspecific
and therefore requires recruitment to the poly(A) site by multiple proteinprotein and
proteinRNA interactions. This recruitment is facilitated by Fip1’s recognition of Urich
USEs along with hexamer recognition by CPSF160. Additionally, Fip1 alone has been
shown to stimulate PAP in a Urich sequence dependent manner of RNAs containing
both canonical and noncanonical hexamers (44). The additional involvement of CF Im is
necessary for PAP recognition and recruitment in a noncanonical sequence context. The
binding of CF Im to UGUANcontaining sequence elements within the RNA contributes
to the recognition of the poly(A) site by PAP and recruitment of both PAP and Fip1 for
poly(A) synthesis (28).
Fip1 is composed of a Nterminal acidic region known to interact with PAP, a
central conserved region followed by a prolinerich region, and a Cterminal region
composed of both an alternating arginine and aspartate region and an arginine region.
Both the Nterminal and Cterminal region contribute to RNA binding and interestingly,
these regions are highly susceptible to phosphorylation making Fip1 the most phospho
modified core processing component (Figure 34) (44, 99). The phosphorylation of Fip1
may be necessary to regulate premRNA 3’end processing events through interactions
with PAP, the RNA or other processing factors. This can be investigated by solving the
crystal structure of Fip1 alone and in complex with PAP. A crystal structure will confirm
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the regions necessary for PAP interaction and provide insight into how modifications to
the PAPFip1 interface may affect processing.

Purification and Expression Attempts of Fip1
The Fip1 construct consisting of the fulllength protein with an amino terminal
hexahistidine tag was initially used to express and purify the protein in E. coli. Attempts
to purify the Fip1 construct using various nickel bead resins, expression using the
autoinduction protocol (100), and dual transformation with the addition of the PAP513
plasmid were unsuccessful. There were no observable changes among various nickel
bead slurries to the purification or improvement in the expression of Fip1 with the Studier
autoinduction protocol. The purification of the fulllength construct resulted in no
obvious Fip1 band when observed by SDSPAGE. The inclusion of the PAP513 plasmid
during the transformation step did not stabilize Fip1 expression and resulted in either
PAP513 expression or no protein expression.
Due to expression and purification problems in bacteria, we turned to an insect
cell expression system. There was no protein visible by SDSPAGE following
purification from either SF9 or HighFive cells. This led us to believe the baculovirus
stock containing the Fip1 cDNA needed to be further amplified to allow for efficient viral
infection and expression from Fip1. Multiple rounds of infection were performed to
amplify the virus, followed by subsequent screening for Fip1 expression of the amplified
virus. This, however, did not improve the insect cell expression of Fip1 and resulted in
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the pursuit of a more stable Fip1construct utilizing a maltose binding protein (MBP) with
a dual affinity tag.
The MBP vector can be used to improve the solubility and stability of proteins
expressed in bacteria (101). Fulllength Fip1 was cloned into the MBP dual vector. The
vector consists of an amino terminal MBP tag containing an internal hexahistidine tag
and a tobacco etch cleavage site following the MBP tag and before the cloning site.
Expression in E. coli and purification yielded multiple bands resembling Fip1 fragments.
To ensure that the multiple fragments were the Fip1 construct the tag was removed via a
Tobacco etch virus (TEV) protease cleavage step and purified away from the MBP tag
using batch nickel beads. This resulted in multiple Fip1 bands in the flowthrough
fraction confirming all fragments were Fip1. This elution pattern suggests the Cterminal
region of Fip1 is prone to proteolytic degradation which correlates with the full length
protein disorder prediction plots (Figure 35). Alternatively, the multiple banding pattern
could represent alternative spliced forms of Fip1 and/or various forms of modified Fip1,
both of which have been previously described (44, 99).
Despite the degradation, Fip1 fragments were incubated with PAP513 to identify
which fragments maintained a PAP interaction. Fragment interaction was determined by
incubation with the amino hexahistidine tagged PAP513 and purified by NiNTA beads
and additionally by coelution on a gel filtration column. None of the fragments of Fip1
copurified with PAP513 off the batch nickel column while the gel filtration column gave
an estimated molecular weight of 69 kDa for the complex. The apparent molecular
weight of PAP513 alone is 48 kDa suggesting a 20 kDa size fragment of Fip1 maintains
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an interaction with PAP based on the gel filtration experiment. Due to the small size of
the Fip1 fragment and the expression and purification issues with fulllength Fip1 a
truncation mutant of Fip1 known to interact with PAP was cloned.

Construct 1355 of Fip1 Does not Stabilize Expression and Purification Attempts
Previous biochemical data demonstrate a region encompassing residues 1355 and
containing the acidic and conserved region of Fip1 is able to retain an interaction with
PAP513 in pulldown experiments (44). This Fip1 truncation (1355Fip1) was
constructed using the dual MBP vector previously described. In comparison to the full
length, the 1355Fip1 resulted in more protein visible by SDSPAGE during the NiNTA
purification step (Figure 36). However, 1355Fip1 also displayed a similar multiple
banding pattern, which was previously shown to be the result of degradation. The
interaction with PAP513 was investigated by both gel filtration and coelution on an
affinity column after the MBP tag was removed. This resulted in a similar outcome as
described for the full length fragments, where PAP513 did not coelute with 1355Fip1
using affinity chromatography (Nickel resin). The gel filtration results gave an estimated
molecular weight of 242 kDa and 157 kDa for the complex. The approximate molecular
weight of 1355Fip1 alone is 40 kDa. This molecular weight suggests a large complex of
PAP513 with multiple 1355Fip1 fragments that was confirmed by the multiple banding
pattern on SDSPAGE.
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1355Fip1 did not demonstrate stable expression or purification based on the
multiple banding pattern and consequently a Cterminal hexahistidine tag was added to
the dual MBP1355Fip1 (1355Fip1C) vector with the hope to preclude degradation at
the Cterminus. Multiple trials to purify 1355Fip1C were not successful and multiple
Fip1 fragments were still apparent. Lastly, to address instability issues Fip1 was cloned
into a dual expression vector with PAP513 with the hope of increasing its expression and
stability. The 1355Fip1 and PAP513 constructs were cloned into the pET Duet vector
(Invitrogen) with and without the dual HisMBP tag. Expression and purification
attempts did not show an improvement from previous Fip1 trials.

Point Mutation in Fip1 Constructs
A single point mutation introducing a tryptophan in the place of a glycine at
residue 293 was identified in all of the Fip1 constructs. To rule out the possibility that
the point mutation prevented the proper expression and purification of Fip1 all of the
Fip1 constructs were corrected and confirmed by sequence analysis. This resulted in
corrections to MBP1355Fip, MBPFip1 full length, and the pET duet expression vector.
Subsequent expression and purification protocols were performed on the corrected Fip1
constructs and analyzed for an improvement in the yield or stability of Fip1 protein.
Changes to residue 293 did not show a noticeable improvement when compared to the
previous trials and suggests Fip1 is susceptible to degradation that can not be stabilized
by PAP513 interactions.

101

Conclusions
Fip1 interacts with PAP and other premRNA 3’end processing components via
its Nterminal domain and additionally makes contacts to the RNA with its Cterminal
arginine rich region (44). These regions cooperate in binding Urich USE’s and
establishing interactions with its processing partners for PAP recruitment and recognition
of the poly(A) site (28, 44). In this respect, the ability to establish dual contacts requires
a flexible domain architecture representative of Fip1 and noted by a highly disordered
prediction plot. The flexible domain architecture of Fip1 makes it a difficult candidate
for crystallographic trials due its susceptibility to proteolytic degradation. Additionally,
the different isoforms of Fip1 and multiple phosphorylated states make it difficult to
establish a purification scheme yielding one major Fip1 band. The difficulty in
optimizing the expression and purification of Fip1 was evident in the described data
above and surprisingly, Fip1 stability was not increased with the inclusion of PAP513.
This suggests it may be necessary to include all Fip1 binding partners to create a more
rigid complex across the length of Fip1 or construct a very small Fip1 fragments that still
maintains binding interactions.
The recent crystal structure of yeast poly(A) polymerase (Pap1) in complex with
a 25 amino acid fragment of yeast Fip1 also makes note of the disordered nature of Fip1
(22). The yeast Fip1 fragment shows a high propensity to be disordered in the absence of
Pap1. This is likely to be more severe in the human Fip1 due to the presence of the acidic
Cterminal extension and confirmed by the above results.
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Introduction: Clp1
Human Clp1 was originally identified as an essential component of cleavage
factor II (CF IIm) in premRNA 3’end processing and is able to interact with both CPSF
and CF Im. The interaction of Clp1 with CF Im is through direct interaction with the
Nudix domain of CF Im25 demonstrated by pulldown assays (unpublished, (93). Recent
data suggest Clp1 functions as an RNAspecific 5’kinase crucial in both tRNA
maturation and phosphorylation of interfering RNAs. The 5’kinase activity has been
demonstrated in vitro for the phosphorylation of siRNAs and subsequent incorporation
into the RNAinduced silencing complex. The association of Clp1 with the tRNA
splicing endonuclease complex and its 5’kinase activity has been demonstrated in vitro
and in vivo confirming Clp1’s function in tRNA splicing (62, 94, 102).
In yeast, the Clp1 homologue similarly plays a role in premRNA 3’end
processing and is additionally essential for cell viability. Interestingly, the human Clp1 is
not able to complement a yeast Clp1 knockout and likewise the yeast Clp1 lacks in vitro
5’kinase activity previously established for the human protein. This suggests that
although these homologous proteins may share a similar domain architecture they may
have very different functions (Figure 37). In order, to address the differences between
the human and yeast Clp1 a crystal structure of the human Clp1 is necessary to compare
domain architecture and substrate interactions; a crystal structure of Clp1 in complex
with CF Im25 will be pursued as well.
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Expression and Purification
The initial trials to express and purify human Clp1 with a hexahistidine affinity
tag utilized a bacterial expression system. Multiple cell lines including Rosetta, BL21,
and pLysE cells were used in parallel with several different growth conditions
(Autoinduction method, low induction temperature, short induction period) and resulted
in minimal or no expression of Clp1. The pLysE cells showed the highest Clp1
expression level following purification. However, the band corresponding to the
molecular weight of Clp1 could not be confirmed by mass spectrometry methods. The
inability to obtain protein confirmation suggests the expression of Clp1 is unstable.
In addition, the cDNA of full length and an amino terminal truncation mutant of
Clp1 were cloned into the HisMBP dual vector system in an attempt to increase the
expression level. The truncation mutant (N43Clp1) was constructed based on the
estimated 43 Nterminal residues of Clp1 predicted to be disordered by disorder
prediction programs and the disordered regions of the yeast Clp1 structure, which lacks
the first 18 residues. Neither the full length or N43Clp1 dual MBP vectors showed an
improved expression level. The poor expression of N43Clp1 may be due to the
truncation itself, which interrupts a sevenstranded  sandwich.
The poor expression using the bacterial system led us to pursue expression of
Clp1 using insect cells. The expression and purification of a hexahistidine tagged human
Clp1 showed an increased expression level and the Clp1 protein was confirmed by mass
spectrometry. Clp1 expressed in insect cells has a very clean elution following NiNTA
purification with a yield of approximately 1 mg/L.
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Complex Crystallization Trials with CF Im25 and Clp1
The complex between CF Im25 and Clp1 was formed by incubation of Clp1 with
CF Im25 in a 1:2 ratio with the addition of a 10fold excess of ATP. The initial buffers
consisting of 0.02 M TrisHCl pH 7.5 and 200 mM KCl or 0.2 M TrisHCl pH7.5 and 0.2
M Ammonium sulfate showed very low solubility of the complex at concentrations
between 1.5 and 5 mg/mL. To increase the solubility, buffer screens were examined
looking for a decrease in protein precipitation at concentrations between 2.5 and 3
mg/mL. Hepes buffer at 0.1 M or TrisHCl buffer pH 7.8 and 150 mM NaCl increase the
solubility of the Clp1 complex and show promising precipitant aggregation using the
crystallization conditions previously described for the yeast Clp1 (20).

Dynamic Light Scattering Experiments
Dynamic light scattering experiments were carried out on the Clp1 and CF Im25
complex to investigate putative changes in the oligomeric state with the addition of ATP
(Figure 38). Experiments conducted with and without ATP show two distinct peaks: one
of very high molecular weight and polydispersity, which is more prevalent upon addition
of ATP. The small peak has an ideal polydispersity ranging from 1825% and an average
molecular weight of 125 kDa. These DLS data suggest that there may be two distinct
oligomeric states of the complex or each peak is representative of each individual protein.
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Additionally, ATP addition does not seem to increase the solubility of the complex as
previously thought.
To address the possibility that Clp1 and CF Im25 may not be forming a complex,
DLS experiments were performed with Clp1 alone. The DLS results show a very large
molecular weight and high polydispersity peak much like the larger peak observed with
the complex.

Conclusions
The investigation of the Clp1 and CF Im25 complex has provided initial results
that are promising for obtaining a crystal structure of a complex. The complex is more
soluble in 0.1 M Hepes pH 7.0 or 0.1 M TrisHCl pH 7.8 and shows promising spherulite
formation in the crystallization conditions reported for the yeast enzyme (0.1M Hepes pH
7.0 and 1420% (v/v) PEG 8000) (20). Additionally, dynamic light scattering assays
with and without ATP indicate that the addition of ATP may not stabilize the complex.
Future experiments involving screening around the yeast crystal conditions by varying
the pH and gel filtration assays to confirm complex association will prove valuable.
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Figure 24: Diagram of the Disordered Regions of CF Im68
The domain architecture is shown above the disorder prediction profile (PoodleS) of
CF Im68. A high probability of disorder is represented by a the red line above the 0.5
mark. Most of the Cterminal region of CF Im68 is predicted to be disordered (98).

107

Figure 25: Dynamic Light Scattering of the CF Im complex
Dynamic light scattering with CF Im demonstrates a large oligomeric complex,
represented by the second peak, with a estimated molecular weight of 8625 kDa
(represented by the radius of the curve) and a high polydispersity of 74%.
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Figure 26: Domain architecture of the 68kDa truncation mutants
Complex association of CF Im25 and CF Im68 was investigated using truncation mutants
comprising the Nterminal region of CF Im68 (N68 and residues 1160) and only the
RNA recognition motif (RRM) (RRM68 and residues 81160).
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Figure 27: Gel filtration profile of CF Im25 and N68 complex
N68 and CF Im25 elute separately off a Superdex 200 (GE Healthcare) gel filtration
column. The N68 protein elutes prior to CF Im25 suggesting it forms a larger oligomer.
The blue line represents absorbance at 280nm.
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Figure 28: Dynamic light scattering of CF Im25 and N68 complex
DLS data demonstrate a high polydispersity (41%) for the complex suggesting it may be
a poor candidate for crystallization experiments.
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Figure 29: Secondary structure prediction of SELEX 1 RNA
An example of a secondary structure prediction (MFOLD) of 60mer SELEX 1 RNA with
a minimal G = 3.41 (initially 4.9). The fold prediction suggests a minimal energy
state is maintained with a hairpin loop structure (103).
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Figure 30: Crystal of CF Im25 and N68
Crystal of the complex set up in a 1:2 ratio of N68 to CF Im25 at 2.5 mg/mL in the
condition: 0.1 M Magnesium acetate, 10% (w/v) PEG, and 10% (v/v) glycerol at 12C.
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Figure 31: Architecture of bovine PAP and regions involved in binding CF Im25
The domain architecture of full length bovine PAP is presented with the cyan region
indicating the ordered residues in the PAP513 structure, the active site aspartic acid
residues are indicated (D), as well as the positions of the nuclear localization signals
(NLS1 and NLS2)(50). A. Represents the region in the Cterminal truncated bovine
PAP (PAP513) that maintains interaction with CF Im25(41). B. Represents previous data
suggesting the Cterminal residues 670739 of murine PAP are necessary for CF Im25
interaction(64).
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Figure 32: Truncation mutant of bovine PAP
The domain architecture of the full length and truncated bovine PAP (PAP513) protein.
PAP513 contains the active site region necessary for polymerization.
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Figure 33: Gel shift of PAP513 and CF Im25 complex
Both CF Im25 and PAP513 are capable of binding 32Plabeled ATP independently,
evident by the change in mobility upon protein addition. In addition, CF Im25 and
PAP513 can form a complex as indicated by a small shift in comparison to the supershift
seen with PAP513 alone (indicated with an arrow).
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Figure 34: Domain architecture of Fip1 and regions interacting with PAP513
The human Fip1 protein is composed of an acidic Nterminus (Acidic), central conserved
region (Conserved), proline rich region (Prich), and a Cterminal region composed of
both an alternating charged domain (RD) and an arginine rich domain (Rrich). The
regions of Fip1 that are involved in PAP513 interactions are presented as described (44).
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Figure 35: Disorder prediction profile of human Fip1
The disorder prediction profile of Fip1 (POODLE) shows multiple regions over the entire
length of the protein have a high probability of being disordered (98).
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Figure 36: SDSpage gel of NiNTA purified 1355Fip1 before and after TEV
cleavage
A. NiNTA purification of MBP1355Fip1 (arrow indicates protein of interest). B. Ni
NTA purification following TEV cleavage of both the full length MBPFip1 and the
MBP1355Fip1. The cleaved protein elutes in the flow through fraction indicated by the
arrows and displays a multiple banding pattern due to proteolytic degradation.
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Figure 37: Domain architecture of human Clp1
Human Clp1 is composed of an Nterminal domain as shown in red, a central region
involved in nucleotide binding, and a Cterminus shown in blue.
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Figure 38: Dynamic light scattering of Clp1/CF Im25 complex at 15C
A. DLS of the Clp1/CF Im25 complex in the conditions 0.1 M Hepes pH 7.0 and 150 mM
NaCl. The polydispersity (pD) of the first peak is 21% and molecular weight (MW) is
169 kDa and the pD for the second peak is 46.8% with a MW of 55958 kDa. B. DLS of
the Clp1/CF Im25 complex and ATP in the same conditions. The pD of the first peak is
37% and MW is 96 kDa and the pD for the second peak is 68.6% with a MW of 28970
kDa. Two distinct oligomeric states are apparent in both experiments however, the
polydispersity increases upon addition of ATP.
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Materials and Methods

Protein Purification
The baculovirus dual expression vector containing the cDNA of the 25 kDa
subunit and 68 kDa subunit of human cleavage factor Im (CF Im) was a gift of Dr. G.
Gilmartin (University of Vermont) and the purification has been previously described
(27). The construction of the plasmid expressing the 25 kDa subunit of CF Im with a dual
6xHismaltose binding protein (MBP) affinity tag was previously described (97). The 68
kDa RRM (81160 residues; 68RRM) and the Nterminal (1160 residues; N68)
constructs with amino terminal glutathione affinity tags was a gift from Dr. W. Keller
(Biozentrum, Basel, Switzerland) (41). The 68RRM and N68 were expressed in Rosetta
2 (DE3) pLysS cells (Novagen) and grown in LB medium for 24 hours following
induction with 0.4 mM IPTG. Cells were lysed at 4C by sonication in a buffer
containing 1 x phosphate buffered saline pH 7.3 and a protease inhibitor tablet (Roche).
The lysate was centrifuged at 12,000 x g prior to loading on a GST affinity column (GE
Healthcare). The GST tag was removed by digestion with Tobacco etch virus (TEV)
protease cleavage step and a second GSTaffinity column (GE Healthcare) removed
undigested material. Further purification required a final Capto S column, cation
exchange (GE Healthcare). Protein concentration was determined by Bradford assay and
combined in a 1:1 or 1:2 mM ratio with CF Im25. Proteins were concentrated to
approximately 14mg/mL (Millipore Amicon Ultra15), flash frozen and stored at 80C.
The bovine PAP513 plasmid was a gift from Dr. W. Keller and purified as
previously described (50). The crosslinked PAP513 to an oligo(A) 15mer was a gift
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from Qin Yang (University of Vermont). Proteins were concentrated to 36 mg/mL at a
ratio of 1:1 or 1:2 (PAP513:CF Im25) with or without nucleotide.
The construction of the plasmid expressing the human Fip1 protein with a
hexahistidne affinity tag and human Fip1 baculovirus was a gift from Dr. W. Keller and
purified as previously described (44). The cDNA of human Fip1 was cloned into the dual
maltose binding protein affinity tag vector as described (101). The primers used to
construct the 1355Fip1 by insertion of a stop codon are:
5’CAATTTTAGCAAATAACCTCCGTTTTTCCCTCCAGG3’ and
5’CCTGGAGGGAAAGGATATTTGCTAAAATTG3’. Construction of the dual MBP
vector required the primers
5’GGGGACCACTTTGTACAAGAAAGCTGGGTTATTATTCTGCAGGTGTAGCTT
CGGA3’, 5’GAGAACCTGTACTTCCAGGGTATGTCGGCCGGCGAGGTC3’,
5’GGGGACAAGTTTGTACAAA3’ and 5’TCCAGGTGCATCAAGGTCTAC3’. The
tryptophan to glycine point mutation at amino acid 293 in Fip1 was corrected with the
primers 5’GCCAATTCAAGCGTTGGGAAGTGGCAGGATCG3’ and
5’CGATCCTGCCACTTCCCAACGCTTGAATTGGC3’. Lastly, the duet vector was
constructed with the following primers for Fip1:
5’TGATATCAATGTCGGCCGGCGAG3’ and
5’GTGGTACCTTATTTGCTAAAATTGTTGTC3’ and for PAP513
5’ATGGTCGACGATGGCTCACCAT3’ and
5’CGACTAGTCTAGACGCCTTCTGTTGAATG3’. The MBP fusion and duet proteins
were transformed into Rosetta DE3 pLysS cells (Novagen), lysed in 20 mM TrisHCl pH
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8.0, 200 mM NaCl, and 25 mM Imidazole pH 7.9, and purified by NickelNTA column
(Qiagen). The eluted fractions were dialyzed into 25 mM TrisHCl pH 7.5, 100 mM KCl,
and 10% (v/v) glycerol and subsequently cleaved by TEV protease at a 1:20 ratio and
loaded on a second NickelNTA column. Lastly, Fip1 was purified on an anion exchange
mono Q column by increasing ionic strength from a start buffer of 25 mM TrisHCl pH
7.5, 100 mM KCl, and 10% (v/v) glycerol.
The Clp1 hexahistidine affinity tagged construct was a gift from Dr. W. Keller
(93). The Clp1 cDNA was cloned into a dual MBP vector by Justin Meyette as
previously described (69). The Clp1 baculovirus was a gift from Dr. G. Gilmartin and
expressed in SF9 insect cells (Gibco). All Clp1 constructs were lysed in 50 mM TrisHCl
pH 8.0, 200 mM NaCl, 1 mM PMSF, and protease inhibitor tablet (Roche), centrifuged at
10,000 x g and purified using NiNTA affinity resin (Qiagen). The Clp1 protein was
eluted with a step gradient of increasing imidazole concentration from 50, 100, 250, and
500mM imidazole. The eluted protein fractions containing Clp1 were dialyzed into 0.1
M Hepes pH 7.0, 150 mM NaCl, and 1 mM DTT or 20 mM TrisHCl pH 7.8, 150 mM
NaCl, and 0.5 mM TCEP. To form the complex Clp1 and CF Im25 were incubated in a
1:2 ratio on ice with a 10fold excess of ATP and concentrated to approximately 2.5
mg/mL with an Amicon Ultra 4 (Millipore).
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RNA preparation
The DNA oligonucleotides used to synthesize the 60mer SELEX RNA is
described in (27). The remaining primers used to generate the 40mer SELEX, PAP alpha
and PAP gamma sequences are: 5’GGCGCGCGGTATACATTA 3’,
5’ ATTTAGGTGACACTATAGACATGATGTATGTAGTGTCT 3’, 5’
ATTTAGGTGACACTATAGCTGTACTCCTTGTATTTTT 3’,
ATTTAGGTGACACTATAGTTGTAAACAGATGATGTATT 3’,
5’ ATTTAGGTGACACATATAGACCATGTAATTCTTGTAATA 3’,
and 5’ ATTTAGGTGACACTATAGTGTAAATGAAGTCGTATGAT 3’.
Each oligonucleotide was annealed and transcribed by T7 RNA polymerase (Epicentre),
and the transcripts were gel purified.

Electromobility Shift Assays
Gel shift assays were performed as previously described in 25 mM or 50 mM KCl
Buffer D (20 mM HEPES pH 7.9, 10% (v/v) glycerol, 0.2 mM EDTA, 0.5 mM DTT, 0.1
mM PMSF) and may also include 32P ATP (27). The RNAprotein complexes were
resolved on a 3% nondenaturing polyacrylamide gel at 4C. The 32P ATP protein
complexes were resolved on a 6% nondenaturing polyacrylamide gel at 4C.
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Oligomeric State Determination
Size exclusion chromatography was performed with a Superdex 75 column and a
Superdex 200 column (GE Healthcare). The protein sample or molecular mass standards
were applied to the columns as previously described (97). Dynamic Light Scattering
experiments were conducted at a protein concentration ranging from 0.3 – 0.4 mg/mL
over the temperature range of 5C  25C (Dynapro, Wyatt). At each temperature point
three sets of 40 measurements were made to accurately measure the molecular weight
and polydispersity. The standard protein buffer consisted of 10% (v/v) glycerol, 50 mM
KCl, 20 mM TrisHCl pH 7.5  8.0. Adjustments to this buffer according to
polydispersity included CHES pH 9.0, Citric Acid pH 5.0, HEPES pH 7.0, 0–15%
glycerol, 50 – 200 mM KCl or NaCl, and addition of UGUAN RNA, Ap4A, or ATP.
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CHAPTER 4:
Future Directions and Conclusions
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Introduction
The maturation of the premRNA 3’end appears deceptively simplistic when
broken down into stepwise events entailing endonucleolytic cleavage followed by
poly(A) addition. However, the complexity of the premRNA 3’end processing
mechanism becomes apparent with the multiple factors involved and their established
link to steps preceding and following, cleavage and polyadenylation. Factors recruited
early to the premRNA affect the efficiency of downstream processing events and may
also be involved in multiple stages of processing not yet established, but suggested by
biochemical data. It, therefore, becomes important to decipher the protein interfaces
necessary for coupling these interactions and provide insight into how cleavage and
polyadenylation factors are coordinated on the RNA and within the processing
machinery. This can be addressed crystallographically by obtaining complex structures
to define the regions necessary to facilitate proteinprotein or proteinRNA interactions
and additionally can aid in establishing new recognition surfaces. The crystallographic
investigation of the protein complexes presented can be used to reevaluate the minimal
interactions necessary for complex association and readdress suitable complex
candidates.

Cleavage Factor Im
The pursuit of a CF Im complex structure was not successful due to degradation of
the Cterminal region of the 68 kDa subunit and intrinsic flexible regions as suggested by
disorder prediction plots. In order to further investigate a CF Im complex, improvement
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to the expression and purification method of the 68 kDa truncation mutants is necessary.
This would involve recloning into a more efficient vector, such as the HisMBP dual
vector or a minimal hexahistidine tagged system. The involvement of CF Im25 in mitotic
spindle assembly separate from the 68 kDa subunit demonstrates that CF Im25 is involved
in other complexes and functions outside of premRNA 3’end processing (53).
Understanding what mechanisms drive the interaction between CF Im25 and CF Im68 will
be important in successfully readdressing a crystal complex.

Alternative methods
Pulldown assays have demonstrated that the 68 kDa RRM region is sufficient in
maintaining an interaction with the entire CF Im25 protein (41). It would be worthwhile
to investigate the minimal interaction between CF Im25 and the truncation mutants of
CF Im68 via limited proteolysis experiments. The limited proteolysis assays will
determine if there are additional flexible regions not stabilized through complex
interactions and can be determined by additional bands on an SDSPAGE following
proteolytic cleavage. The exact position of proteolytic digestion can be determined by
mass spectrometry. This information can then be used to reconstruct minimal expression
vectors for both the 25 kDa and 68 kDa subunits and improve the complex crystallization
process to eliminate potential flexible regions that prevent improper crystal packing
interactions.
Investigating the affinity of complex formation between the 25 kDa and 68 kDa
subunit can be defined by complex association at increasing salt concentrations. This
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would suggest whether these subunits are suitable candidates for crystallization and can
be addressed using pull down assays as previously described (41). Intolerance to high
concentrations of salt would suggest a weak interaction between the two subunits and
may result from a requirement of additional binding partners.

Determining more suitable candidates
The data presented in Chapter 3 suggests the interactions of various premRNA
3’end processing factors described biochemically may require additional stabilizing
factors to allow for crystallographic investigation. However, alternative binding partners
capable of forming a complex with CF Im25 can be investigated by pulldown assays
using nuclear extract. These experiments have been preformed previously by the
Gilmartin lab and demonstrated the association of CF Im25 with chromatin remodeling
factors (Brown, unpublished data). This experiment can be repeated with increasing
amounts of salt to determine a tight binding complex. In addition, it would be necessary
to determine if the interactions are direct interactions between CF Im25 and the associated
protein. This can partially be addressed by RNase treatment of the complex fraction.
Loss of complex association following RNase treatment suggests RNA is necessary to
facilitate binding. The direct association with CF Im25 can then only be determined by
direct interaction with the recombinant protein by pulldown, dynamic light scattering, or
gel filtration experiments.
A brute force method can also be applied to obtain a complex crystal structure.
This would involve combining all the expressed and purified proteins mentioned in
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Chapter 3 and setting up crystallization trails under the assumption that the most likely
candidates to interact will crystallize as a complex. This might prove to identify the
minimal components necessary to form a complex.

Is C F Im25’s nucleotide binding affinity necessary for its function?
The results from Chapter 2 demonstrate that CF Im25 is able to bind to Ap4A and
additionally to ATP. However, the nucleotide binding potential of CF Im25 does not have
an affect on in vitro cleavage and polyadenylation assays. To determine the necessity of
nucleotide binding for the function of CF Im25 in vitro, residues residing within the
binding pocket such as arginine 63 (R63), arginine 150 (R150), and lysine 172 (K172)
can be mutated to methionines (M) to disrupt the hydrogen binding potential with the 
and  phosphates and prevent nucleotide binding. Initial in vitro assays of the
recombinant mutant can be used to verify an inability to bind nucleotides by steady state
fluorescence experiments. Following confirmation, the mutant CF Im25 can be used to
reconstitute wild type CF Im25 in CF Im25 knockdown cells. Knockdown of endogenous
CF Im25 can be achieved by siRNA targeting in Hela cells and subsequently reconstituted
with the mutant plasmid under a constitutive promoter. Changes affecting premRNA 3’
end processing can be assayed between wild type and mutant CF Im25 by sequencing of
the two poly(A) polymerases (PAPOLG and PAPOLA) mRNA pools in Hela nuclear
extracts, to reflect variation in the total amount of polyadenylated mRNA of a
noncanonical and canonical poly(A) site. Previous work has demonstrated that CF Im is
necessary for efficient processing of premRNA containing noncanonical hexamers, in
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the case of PAPOLG, and additionally enhances the 3’end processing of canonical pre
mRNA, PAPOLA (28). In this manner the importance of nucleotide binding to pre
mRNA 3’end processing in vitro can be further assessed.
Chapter 2 establishes the binding affinity of CF Im25 to ATP and Ap4A and
demonstrates the addition of Ap4A has no affect on in vitro cleavage and polyadenylation
assays. Henceforth, the role of the Nudix domain of CF Im25 in nucleotide binding is
unclear. The conserved Nudix domain of CF Im25 may be important for RNA binding
and/or recognition. This can be addressed partially by the experiment described above.
If variations in 3’ processed canonical and noncanonical premRNA are apparent this
may be due to the inability of CF Im25 to bind and recognize UGUAN containing RNAs.
The importance of these residues, R63, R150 and K172, to facilitate RNA binding can
then be addressed by gel shift assays using the SELEX 1 60mer RNA as previously
described (27). The SELEX 1 RNA contains the UGUAN element recognized by CF Im
and capable of forming a complex by gel shift. To test this hypothesis mutation of key
residues in the CF Im25 subunit of the CF Im dual baculovirus vector need to be
constructed. Investigating the ability of the mutant CF Im25 to bind the SELEX RNA
would also suggest any changes in the ability of CF Im to regulate poly(A) site selection.
Additionally, it would be interesting to see if the proteins CF Im25 associates with via
pulldown assays change with respect to its nucleotide binding potential.

Unresolved Questions
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CF Im25 is a dimer in both the crystal structure and in solution as presented in
Chapter 2. Due to the large dimer interface, 2,700 Å2, between CF Im25 monomers it is
expected CF Im25 remains a dimer when associated with other premRNA 3’end
processing factors however, confirmation of the oligomeric state of the CF Im complex
has yet to be determined. Estimating the stoichiometry of the CF Im subunits by DLS and
gel filtration using the 68 kDa truncation mutants with CF Im25 was not successful and
could be reevaluated by analytical ultracentrifugation. Analytical ultracentrifugation
could estimate the sample portion involved in complex formation and portion that is self
aggregating. Knowing the stoichiometry of the CF Im complex provides information for
setting up future crystallization trials and improves the success rate of obtaining a
complex crystal. In doing so, the assumption can be made that the CF Im25 protein
maintains the same oligomeric state with other binding partners which again can be
helpful in future crystallization attempts.

Cleavage Factor Im25 and Poly(A) polymerase
Evidence for the interaction of CF Im25 with PAP513 was suggested by a
supershift upon the addition of CF Im25 in a gel shift assay presented in Chapter 3. This
experiment alone does not suffice in establishing a tight interaction between both proteins
and must be repeated. The PAP domains necessary to maintain an interaction with CF
Im25 is disputed in the literature and presented both as requiring the Cterminal region of
PAP and maintaining the interaction despite a truncation to the Cterminal region of PAP.
Our evidence so far does not conclusively clarify this issue. It is apparent that PAP513
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alone with CF Im25 does not demonstrate on a gel filtration column what would be
expected of a tightly associating complex as mentioned in Chapter 3. We have shown
CF Im25 and PAP513 elute off of a gel filtration column at their individual, although
overlapping, estimated molecular weights. To better address a complex between CF Im25
and PAP513 the stoichiometry of the complex needs to be determined by
ultracentrifugation methods. In addition, the direct interaction of CF Im25 and PAP513
needs to be confirmed with the recombinant proteins, which has not been conclusive so
far. The interaction could require the addition of the 68 kDa truncation mutant, RNA,
Fip1 or ATP for efficient binding. Evidence for potential binding interactions and
complex association has been demonstrated comprising CF Im, PAP, and Fip1 in the
context of a poly(A) site selection of noncanonical hexamer containing RNA (28).
Further investigation of the minimal PAP513 and CF Im25 complex can be addressed by
increasing the 3’end processing components until a complex molecular weight is
achieved on a gel filtration column or confirmed by pull down assay. Upon confirmation
of a complex, limited proteolysis experiments will confirm the stability of the complex
and the minimal fragments necessary for subsequent crystallization techniques. Based on
previous results the expression and purification of Fip1 was problematic but may be
stabilized upon the addition of the 25 kDa subunit along with PAP513.

Factor Interacting with Pap1
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The pursuit of a Fip1 crystal structure both alone and in complex with PAP513
was unsuccessful due to proteolytic degradation of the flexible regions of Fip1. A
minimal Fip1 complex with PAP513 can be achieved by similar means as the recent
complex of the yeast Pap1 and Fip1 fragment. The sequence of Fip1 is highly divergent
from species to species except for the conserved region comprising residues 135204
(based on the human sequence). The minimal interaction between the human
homologues has been predicted to be maintained by amino acids 1111 of Fip1 and
additionally, fulllength Fip1 interacts with the RBD (residues 366513) and Nterminal
(53214) of PAP by pulldown experiments (44). Increased binding to PAP, in
comparison to residues 1111 of Fip1, is achieved with residues 1355 of Fip1 as
previously mentioned and presented in Chapter 3. Reconstitution of the complex
comprising fragment 1111 of Fip1 and PAP513 can then be subjected to limited
proteolysis to determine if a smaller fragment of either protein can maintain complex
interactions

Alternative methods
Surface entropy reduction can be applied to optimize the crystallization
techniques of any above mentioned protein complexes. This technique is based on
minimizing high entropy surface residues such as lysines, glutamines, and glutamates that
require more energy to bury these residues by forced crystalcrystal contacts (104).
These surface residues can be predicted by the webtool SERp and suggest more suitable,
low entropy residues in their place (105). SER predictions on N68 suggest residues 20
23 (sequence EEFNQEAE), 138139 (EASSKK), and residue 146K are high entropy
135

residues and can be substituted by an alanine to improve crystallization odds.
Additionally, Fip1 1355 shows several high entropy clusters at residue ranges 2123
(EEE), 245247 (EKETA), and 5254 (ENEVERPEEENASA). This technique may
prove useful in future crystallization trials of difficult protein complexes following
adequate optimization of protein expression and purification procedures.

136

REFERENCES

(1)

Bird, G., Zorio, D. A., and Bentley, D. L. (2004) RNA polymerase II carboxy
terminal domain phosphorylation is required for cotranscriptional premRNA
splicing and 3'end formation. Mol Cell Biol 24, 89639.

(2)

Maniatis, T., and Reed, R. (2002) An extensive network of coupling among gene
expression machines. Nature 416, 499506.

(3)

Calvo, O., and Manley, J. L. (2003) Strange bedfellows: polyadenylation factors
at the promoter. Genes Dev 17, 13217.

(4)

Komarnitsky, P., Cho, E. J., and Buratowski, S. (2000) Different phosphorylated
forms of RNA polymerase II and associated mRNA processing factors during
transcription. Genes Dev 14, 245260.

(5)

Bentley, D. L. (2005) Rules of engagement: cotranscriptional recruitment of pre
mRNA processing factors. Curr Opin Cell Biol 17, 2516.

(6)

Proudfoot, N. J., Furger, A., and Dye, M. J. (2002) Integrating mRNA processing
with transcription. Cell 108, 50112.

(7)

Cougot, N., van Dijk, E., Babajko, S., and Seraphin, B. (2004) 'Captabolism'.
Trends Biochem Sci 29, 43644.

(8)

Millhouse, S., and Manley, J. L. (2005) The Cterminal domain of RNA
polymerase II functions as a phosphorylationdependent splicing activator in a
heterologous protein. Mol Cell Biol 25, 53344.

(9)

Morris, D. P., and Greenleaf, A. L. (2000) The splicing factor, Prp40, binds the
phosphorylated carboxylterminal domain of RNA polymerase II. J Biol Chem
275, 3993543.

137

(10)

Graveley, B. R. (2000) Sorting out the complexity of SR protein functions. Rna 6,
1197211.

(11)

Manley, J. L., and Tacke, R. (1996) SR proteins and splicing control. Genes Dev
10, 156979.

(12)

Millevoi, S., Loulergue, C., Dettwiler, S., Karaa, S. Z., Keller, W., Antoniou, M.,
and Vagner, S. (2006) An interaction between U2AF 65 and CF I(m) links the
splicing and 3' end processing machineries. EMBO J 25, 485464.

(13)

Zhao, J., Hyman, L., and Moore, C. (1999) Formation of mRNA 3' ends in
eukaryotes: mechanism, regulation, and interrelationships with other steps in
mRNA synthesis. Microbiol Mol Biol Rev 63, 40545.

(14)

Wahle, E., and Rüegsegger, U. (1999) 3' End processing of premRNA in
eukaryotes. FEMS Microbiol Rev 23, 27795.

(15)

MinvielleSebastia, L., and Keller, W. (1999) mRNA polyadenylation and its
coupling to other RNA processing reactions and to transcription. Curr Opin Cell
Biol 11, 3527.

(16)

Mandel, C. R., Bai, Y., and Tong, L. (2008) Protein factors in premRNA 3'end
processing. Cell Mol Life Sci 65, 1099122.

(17)

Keller, W., and MinvielleSebastia, L. (1997) A comparison of mammalian and
yeast premRNA 3'end processing. Curr Opin Cell Biol 9, 32936.

(18)

Dichtl, B., and Keller, W. (2001) Recognition of polyadenylation sites in yeast
premRNAs by cleavage and polyadenylation factor. Embo J 20, 3197209.

(19)

Licatalosi, D. D., Geiger, G., Minet, M., Schroeder, S., Cilli, K., McNeil, J. B.,
and Bentley, D. L. (2002) Functional interaction of yeast premRNA 3' end
processing factors with RNA polymerase II. Mol Cell 9, 110111.

(20)

Noble, C. G., Beuth, B., and Taylor, I. A. (2007) Structure of a nucleotidebound
Clp1Pcf11 polyadenylation factor. Nucleic Acids Res 35, 8799.

138

(21)

PerezCanadillas, J. M. (2006) Grabbing the message: structural basis of mRNA
3'UTR recognition by Hrp1. Embo J 25, 316778.

(22)

Meinke, G., Ezeokonkwo, C., Balbo, P., Stafford, W., Moore, C., and Bohm, A.
(2008) Structure of yeast poly(A) polymerase in complex with a peptide from
Fip1, an intrinsically disordered protein. Biochemistry 47, 685969.

(23)

Li, X., Romero, P., Rani, M., Dunker, A. K., and Obradovic, Z. (1999) Predicting
Protein Disorder for N, C, and Internal Regions. Genome Inform Ser Workshop
Genome Inform 10, 3040.

(24)

Balbo, P. B., Toth, J., and Bohm, A. (2007) Xray crystallographic and steady
state fluorescence characterization of the protein dynamics of yeast polyadenylate
polymerase. J Mol Biol 366, 140115.

(25)

Balbo, P. B., and Bohm, A. (2007) Mechanism of poly(A) polymerase: structure
of the enzymeMgATPRNA ternary complex and kinetic analysis. Structure 15,
111731.

(26)

Bard, J., Zhelkovsky, A. M., Helmling, S., Earnest, T. N., Moore, C. L., and
Bohm, A. (2000) Structure of yeast poly(A) polymerase alone and in complex
with 3'dATP. Science 289, 13469.

(27)

Brown, K. M., and Gilmartin, G. M. (2003) A mechanism for the regulation of
premRNA 3' processing by human cleavage factor Im. Mol Cell 12, 146776.

(28)

Venkataraman, K., Brown, K. M., and Gilmartin, G. M. (2005) Analysis of a
noncanonical poly(A) site reveals a tripartite mechanism for vertebrate poly(A)
site recognition. Genes Dev 19, 131527.

(29)

Higgs, D. R., Goodbourn, S. E., Lamb, J., Clegg, J. B., Weatherall, D. J., and
Proudfoot, N. J. (1983) Alphathalassaemia caused by a polyadenylation signal
mutation. Nature 306, 398400.

(30)

Flaherty, S. M., Fortes, P., Izaurralde, E., Mattaj, I. W., and Gilmartin, G. M.
(1997) Participation of the nuclear cap binding complex in premRNA 3'
processing. Proc Natl Acad Sci U S A 94, 118938.

139

(31)

Hirose, Y., and Manley, J. L. (1998) RNA polymerase II is an essential mRNA
polyadenylation factor. Nature 395, 936.

(32)

Murthy, K. G., and Manley, J. L. (1992) Characterization of the multisubunit
cleavagepolyadenylation specificity factor from calf thymus. J Biol Chem 267,
1480411.

(33)

Gilmartin, G. M., Fleming, E. S., Oetjen, J., and Graveley, B. R. (1995) CPSF
recognition of an HIV1 mRNA 3'processing enhancer: multiple sequence
contacts involved in poly(A) site definition. Genes Dev 9, 7283.

(34)

Legrand, P., Pinaud, N., MinvielleSebastia, L., and Fribourg, S. (2007) The
structure of the CstF77 homodimer provides insights into CstF assembly. Nucleic
Acids Res 35, 451522.

(35)

Bai, Y., Auperin, T. C., Chou, C. Y., Chang, G. G., Manley, J. L., and Tong, L.
(2007) Crystal structure of murine CstF77: dimeric association and implications
for polyadenylation of mRNA precursors. Mol Cell 25, 86375.

(36)

Qu, X., PerezCanadillas, J. M., Agrawal, S., De Baecke, J., Cheng, H., Varani,
G., and Moore, C. (2007) The Cterminal domains of vertebrate CstF64 and its
yeast orthologue Rna15 form a new structure critical for mRNA 3'end
processing. J Biol Chem 282, 210115.

(37)

Perez Canadillas, J. M., and Varani, G. (2003) Recognition of GUrich
polyadenylation regulatory elements by human CstF64 protein. Embo J 22, 2821
30.

(38)

Kleiman, F. E., and Manley, J. L. (1999) Functional interaction of BRCA1
associated BARD1 with polyadenylation factor CstF50. Science 285, 15769.

(39)

Mirkin, N., Fonseca, D., Mohammed, S., Cevher, M. A., Manley, J. L., and
Kleiman, F. E. (2008) The 3' processing factor CstF functions in the DNA repair
response. Nucleic Acids Res 36, 1792804.

140

(40)

Rüegsegger, U., Beyer, K., and Keller, W. (1996) Purification and
characterization of human cleavage factor Im involved in the 3' end processing of
messenger RNA precursors. J Biol Chem 271, 610713.

(41)

Dettwiler, S., Aringhieri, C., Cardinale, S., Keller, W., and Barabino, S. M.
(2004) Distinct sequence motifs within the 68kDa subunit of cleavage factor Im
mediate RNA binding, proteinprotein interactions, and subcellular localization. J
Biol Chem 279, 3578897.

(42)

Mandel, C. R., Kaneko, S., Zhang, H., Gebauer, D., Vethantham, V., Manley, J.
L., and Tong, L. (2006) Polyadenylation factor CPSF73 is the premRNA 3'end
processing endonuclease. Nature 444, 9536.

(43)

Kolev, N. G., Yario, T. A., Benson, E., and Steitz, J. A. (2008) Conserved motifs
in both CPSF73 and CPSF100 are required to assemble the active endonuclease
for histone mRNA 3'end maturation. EMBO Rep 9, 10138.

(44)

Kaufmann, I., Martin, G., Friedlein, A., Langen, H., and Keller, W. (2004)
Human Fip1 is a subunit of CPSF that binds to Urich RNA elements and
stimulates poly(A) polymerase. Embo J 23, 61626.

(45)

Helmling, S., Zhelkovsky, A., and Moore, C. L. (2001) Fip1 regulates the activity
of Poly(A) polymerase through multiple interactions. Mol Cell Biol 21, 202637.

(46)

Shimazu, T., Horinouchi, S., and Yoshida, M. (2007) Multiple histone
deacetylases and the CREBbinding protein regulate premRNA 3' end
processing. J Biol Chem 282, 44708.

(47)

Wahle, E. (1991) Purification and characterization of a mammalian polyadenylate
polymerase involved in the 3' end processing of messenger RNA precursors. J
Biol Chem 266, 31319.

(48)

Martin, G., Moglich, A., Keller, W., and Doublie, S. (2004) Biochemical and
structural insights into substrate binding and catalytic mechanism of mammalian
poly(A) polymerase. J Mol Biol 341, 91125.

141

(49)

Kerwitz, Y., Kuhn, U., Lilie, H., Knoth, A., Scheuermann, T., Friedrich, H.,
Schwarz, E., and Wahle, E. (2003) Stimulation of poly(A) polymerase through a
direct interaction with the nuclear poly(A) binding protein allosterically regulated
by RNA. Embo J 22, 370514.

(50)

Martin, G., Keller, W., and Doublie, S. (2000) Crystal structure of mammalian
poly(A) polymerase in complex with an analog of ATP. Embo J 19, 4193203.

(51)

Rüegsegger, U., Blank, D., and Keller, W. (1998) Human premRNA cleavage
factor Im is related to spliceosomal SR proteins and can be reconstituted in vitro
from recombinant subunits. Mol Cell 1, 24353.

(52)

Zhou, Z., Licklider, L. J., Gygi, S. P., and Reed, R. (2002) Comprehensive
proteomic analysis of the human spliceosome. Nature 419, 1825.

(53)

Blower, M. D., Nachury, M., Heald, R., and Weis, K. (2005) A Rae1containing
ribonucleoprotein complex is required for mitotic spindle assembly. Cell 121,
22334.

(54)

Bessman, M. J., Frick, D. N., and O'Handley, S. F. (1996) The MutT proteins or
"Nudix" hydrolases, a family of versatile, widely distributed, "housecleaning"
enzymes. J Biol Chem 271, 2505962.

(55)

Mildvan, A. S., Xia, Z., Azurmendi, H. F., Saraswat, V., Legler, P. M., Massiah,
M. A., Gabelli, S. B., Bianchet, M. A., Kang, L. W., and Amzel, L. M. (2005)
Structures and mechanisms of Nudix hydrolases. Arch Biochem Biophys 433,
12943.

(56)

McLennan, A. G. (2006) The Nudix hydrolase superfamily. Cell Mol Life Sci 63,
12343.

(57)

Bailey, S., Sedelnikova, S. E., Blackburn, G. M., Abdelghany, H. M., Baker, P. J.,
McLennan, A. G., and Rafferty, J. B. (2002) The crystal structure of diadenosine
tetraphosphate hydrolase from Caenorhabditis elegans in free and binary complex
forms. Structure 10, 589600.

142

(58)

Cohen, L. S., Mikhli, C., Jiao, X., Kiledjian, M., Kunkel, G., and Davis, R. E.
(2005) Dcp2 Decaps m2,2,7GpppNcapped RNAs, and its activity is sequence
and context dependent. Mol Cell Biol 25, 877991.

(59)

Ranatunga, W., Hill, E. E., Mooster, J. L., Holbrook, E. L., SchulzeGahmen, U.,
Xu, W., Bessman, M. J., Brenner, S. E., and Holbrook, S. R. (2004) Structural
studies of the Nudix hydrolase DR1025 from Deinococcus radiodurans and its
ligand complexes. J Mol Biol 339, 10316.

(60)

Frick, D. N., Townsend, B. D., and Bessman, M. J. (1995) A novel GDPmannose
mannosyl hydrolase shares homology with the MutT family of enzymes. J Biol
Chem 270, 2408691.

(61)

Legler, P. M., Massiah, M. A., Bessman, M. J., and Mildvan, A. S. (2000) GDP
mannose mannosyl hydrolase catalyzes nucleophilic substitution at carbon, unlike
all other Nudix hydrolases. Biochemistry 39, 86038.

(62)

Ramirez, A., Shuman, S., and Schwer, B. (2008) Human RNA 5'kinase (hClp1)
can function as a tRNA splicing enzyme in vivo. Rna 14, 173745.

(63)

Danckwardt, S., Hentze, M. W., and Kulozik, A. E. (2008) 3' end mRNA
processing: molecular mechanisms and implications for health and disease. Embo
J 27, 48298.

(64)

Kim, H., and Lee, Y. (2001) Interaction of poly(A) polymerase with the 25kDa
subunit of cleavage factor I. Biochem Biophys Res Commun 289, 5138.

(65)

Lutz, C. S., Murthy, K. G., Schek, N., O'Connor, J. P., Manley, J. L., and Alwine,
J. C. (1996) Interaction between the U1 snRNPA protein and the 160kD subunit
of cleavagepolyadenylation specificity factor increases polyadenylation
efficiency in vitro. Genes Dev 10, 32537.

(66)

Awasthi, S., and Alwine, J. C. (2003) Association of polyadenylation cleavage
factor I with U1 snRNP. Rna 9, 14009.

(67)

Zhang, R., Zhou, M., Moy, S., Collart, F., Joachimiak, A. . (2006) The 1.9A
crystal structure of teh MutT/nudix family from Enterococcus faecalis.

143

(68)

Gabelli, S. B., Bianchet, M. A., Azurmendi, H. F., Xia, Z., Sarawat, V., Mildvan,
A. S., and Amzel, L. M. (2004) Structure and mechanism of GDPmannose
glycosyl hydrolase, a Nudix enzyme that cleaves at carbon instead of phosphorus.
Structure 12, 92735.

(69)

Tropea, J. E., Cherry, S., Nallamsetty, S., Bignon, C., and Waugh, D. S. (2007) A
Generic Method for the Production of Recombinant Proteins in Escherichia coli
Using a Dual HexahistidineMaltoseBinding Protein Affinity Tag., in
Macromolecular Crystallography Protocols (Doublié, S., Ed.) pp 120, Humana
Press, Totowa.

(70)

Doublié, S. (2007) Production of Selenomethionyl Proteins in Prokaryotic and
Eukaryotic Systems, in Macromolecular Crystallography Protocols (Doublié, S.,
Ed.) pp 91108, Humana Press, Totowa.

(71)

Otwinowski, Z., and Minor, W. (1997) Processing of Xray Diffraction Data
Collected in Oscillation Mode, in Macromolecular Crystallography, Part A pp
307326, Academic Press.

(72)

Terwilliger, T. C. (2000) Maximumlikelihood density modification. Acta
Crystallogr D Biol Crystallogr 56, 96572.

(73)

Vonrhein, C., Blanc, E., Roversi, P., and Bricogne, G. (2007) Automated
Structure Solution with autoSHARP, in Macromolecular Crystallography
Protocols (Doublié, S., Ed.) pp 215230, Humana Press, Totowa.

(74)

Emsley, P., and Cowtan, K. (2004) Coot: modelbuilding tools for molecular
graphics. Acta Crystallogr D Biol Crystallogr 60, 212632.

(75)

Brunger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse
Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R.
J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Crystallography & NMR
system: A new software suite for macromolecular structure determination. Acta
Crystallogr D Biol Crystallogr 54, 90521.

(76)

Laskowski, R. A., McArthur, M. W., Moss, D. S., and Thornton, J. M. (1993)
PROCHECK: a program to check the stereochemical quality of protein structures.
J Appl Cryst 26, 283291.
144

(77)

Rould, M. A. (2006) The same but different: isomorphous methods for phasing
and highthroughput ligand screening. Methods Mol Biol 364, 15982.

(78)

DeLano, W. L. (2002), San Carlos, CA, USA.

(79)

CCP4. (1994) The CCP4 suite: programs for protein crystallography. Acta
Crystallogr D Biol Crystallogr 50, 7603.

(80)

Ames, B. N., and Dubin, D. T. (1960) The role of polyamines in the neutralization
of bacteriophage deoxyribonucleic acid. J Biol Chem 235, 76975.

(81)

Yengo, C. M., Chrin, L. R., Rovner, A. S., and Berger, C. L. (2000) Tryptophan
512 is sensitive to conformational changes in the rigid relay loop of smooth
muscle myosin during the MgATPase cycle. J Biol Chem 275, 254817.

(82)

Rush, J., Moritz, A., Lee, K. A., Guo, A., Goss, V. L., Spek, E. J., Zhang, H., Zha,
X. M., Polakiewicz, R. D., and Comb, M. J. (2005) Immunoaffinity profiling of
tyrosine phosphorylation in cancer cells. Nat Biotechnol 23, 94101.

(83)

Holm, L., and Sander, C. (1997) Dali/FSSP classification of threedimensional
protein folds. Nucleic Acids Res 25, 2314.

(84)

Yoshiba, S., Ooga, T., Nakagawa, N., Shibata, T., Inoue, Y., Yokoyama, S.,
Kuramitsu, S., and Masui, R. (2004) Structural insights into the Thermus
thermophilus ADPribose pyrophosphatase mechanism via crystal structures with
the bound substrate and metal. J Biol Chem 279, 3716374.

(85)

She, M., Decker, C. J., Chen, N., Tumati, S., Parker, R., and Song, H. (2006)
Crystal structure and functional analysis of Dcp2p from Schizosaccharomyces
pombe. Nat Struct Mol Biol 13, 6370.

(86)

Gabelli, S. B., Bianchet, M. A., Bessman, M. J., and Amzel, L. M. (2001) The
structure of ADPribose pyrophosphatase reveals the structural basis for the
versatility of the Nudix family. Nat Struct Biol 8, 46772.

145

(87)

Logan, D. T., Andersson, J., Sjoberg, B. M., and Nordlund, P. (1999) A glycyl
radical site in the crystal structure of a class III ribonucleotide reductase. Science
283, 1499504.

(88)

Nicholls, A., Sharp, K. A., and Honig, B. (1991) Protein folding and association:
insights from the interfacial and thermodynamic properties of hydrocarbons.
Proteins 11, 28196.

(89)

Champagne, K. S., Sissler, M., Larrabee, Y., Doublie, S., and Francklyn, C. S.
(2005) Activation of the heterooctameric ATP phosphoribosyl transferase
through subunit interface rearrangement by a tRNA synthetase paralog. J Biol
Chem 280, 34096104.

(90)

Kisselev, L. L., Justesen, J., Wolfson, A. D., and Frolova, L. Y. (1998)
Diadenosine oligophosphates (Ap(n)A), a novel class of signalling molecules?
FEBS Lett 427, 15763.

(91)

Baxi, M. D., and Vishwanatha, J. K. (1995) Diadenosine polyphosphates: their
biological and pharmacological significance. J Pharmacol Toxicol Methods 33,
1218.

(92)

Sillero, M. A., De Diego, A., Osorio, H., and Sillero, A. (2002) Dinucleoside
polyphosphates stimulate the primer independent synthesis of poly(A) catalyzed
by yeast poly(A) polymerase. Eur J Biochem 269, 53239.

(93)

de Vries, H., Ruegsegger, U., Hubner, W., Friedlein, A., Langen, H., and Keller,
W. (2000) Human premRNA cleavage factor II(m) contains homologs of yeast
proteins and bridges two other cleavage factors. Embo J 19, 5895904.

(94)

Weitzer, S., and Martinez, J. (2007) The human RNA kinase hClp1 is active on 3'
transfer RNA exons and short interfering RNAs. Nature 447, 2226.

(95)

Pearson, W. R., and Lipman, D. J. (1988) Improved tools for biological sequence
comparison. Proc Natl Acad Sci U S A 85, 24448.

146

(96)

Kabsch, W., and Sander, C. (1983) Dictionary of protein secondary structure:
pattern recognition of hydrogenbonded and geometrical features. Biopolymers
22, 2577637.

(97)

Coseno, M., Martin, G., Berger, C., Gilmartin, G., Keller, W., and Doublie, S.
(2008) Crystal structure of the 25 kDa subunit of human cleavage factor Im.
Nucleic Acids Res 36, 347483.

(98)

Shimizu, K., Hirose, S., and Noguchi, T. (2007) POODLES: web application for
predicting protein disorder by using physicochemical features and reduced amino
acid set of a positionspecific scoring matrix. Bioinformatics 23, 23378.

(99)

Ryan, K., and Bauer, D. L. (2008) Finishing touches: posttranslational
modification of protein factors involved in mammalian premRNA 3' end
formation. Int J Biochem Cell Biol 40, 238496.

(100) Studier, F. W. (2005) Protein production by autoinduction in high density
shaking cultures. Protein Expr Purif 41, 20734.
(101) Nallamsetty, S., Austin, B. P., Penrose, K. J., and Waugh, D. S. (2005) Gateway
vectors for the production of combinatoriallytagged His6MBP fusion proteins in
the cytoplasm and periplasm of Escherichia coli. Protein Sci 14, 296471.
(102) Paushkin, S. V., Patel, M., Furia, B. S., Peltz, S. W., and Trotta, C. R. (2004)
Identification of a human endonuclease complex reveals a link between tRNA
splicing and premRNA 3' end formation. Cell 117, 31121.
(103) Walter, A. E., Turner, D. H., Kim, J., Lyttle, M. H., Muller, P., Mathews, D. H.,
and Zuker, M. (1994) Coaxial stacking of helixes enhances binding of
oligoribonucleotides and improves predictions of RNA folding. Proc Natl Acad
Sci U S A 91, 921822.
(104) Cooper, D. R., Boczek, T., Grelewska, K., Pinkowska, M., Sikorska, M.,
Zawadzki, M., and Derewenda, Z. (2007) Protein crystallization by surface
entropy reduction: optimization of the SER strategy. Acta Crystallogr D Biol
Crystallogr 63, 63645.

147

(105) Goldschmidt, L., Cooper, D. R., Derewenda, Z. S., and Eisenberg, D. (2007)
Toward rational protein crystallization: A Web server for the design of
crystallizable protein variants. Protein Sci 16, 156976.

148

